Early Disease Detection System using AI/ML

A PROJECT REPORT

Submitted by

Aekansh (21BCS8544)
Parul (21BCS4234)
Shubham (21BCS8726)
Rishabh (21BCS8350)

in partial fulfillment for the award of the degree of

BACHELOR OF ENGINEERING

IN

COMPUTER SCIENCE WITH SPECIALIZATION IN

BIG DATA ANALYTICS

Chandigarh University

April 2024

BONAFIDE CERTIFICATE

Certified that this project report **"Early Disease Detection System using AI/ML"** is the bonafide work of "**Aekansh Khandelwal, Parul Gogia, Shubham Malik, Pal Rishabh Raj"** who carried out the project work under my/our supervision.

SIGNATURE   **SIGNATURE**

Mr. Aman Kaushik   Dr. Navjeet Kaur
                                                            SUPERVISOR

HEAD OF THE DEPARTMENT   Professor

AIT-CSE   **AIT-CSE**

Submitted for the project viva-voce examination held on

INTERNAL EXAMINER   **EXTERNAL EXAMINER**

TABLE OF CONTENTS

List of Figures

List of Tables

ABSTRACT

Advancements in Artificial Intelligence (AI) and Machine Learning (ML) have revolutionized healthcare, particularly in early disease detection through medical imaging analysis. This study focuses on harnessing these innovations to develop a sophisticated model for early disease detection across various medical domains, with a particular emphasis on skin diseases. By amalgamating diverse datasets and employing advanced algorithms, our methodology aims to pinpoint subtle disease indicators at their inception, enabling timely interventions and tailored treatment strategies. Through meticulous data collection, preprocessing, and exploratory analysis, we lay the groundwork for robust AI models capable of deciphering complex medical imaging data.

Our proposed methodology underscores the integration of domain-specific clinical expertise to ensure the clinical relevance and interpretability of the models. Rigorous validation and evaluation demonstrate the efficacy and generalization capacity of our approach, facilitating its seamless integration into clinical practice. This study represents a significant step forward in leveraging AI and ML for early disease detection, offering promising avenues for improving patient outcomes and streamlining healthcare delivery.

GRAPHICAL ABSTRACT

Figure 1. Graphical Abstract

ABBREVIATIONS

AI: Artificial Intelligence
CT: Computed Tomography
MRI: Magnetic Resonance Imaging
CNN: Convolutional Neural Networks
HIPAA: Health Insurance Portability and Accountability Act
GDPR: General Data Protection Regulation
RNN: Recurrent Neural Networks
SVM: Support Vector Machine
ECG: Electrocardiogram
ML: Machine Learning
IRB: Institutional Review Boards
ROI: Region of Interest
LRP: Layer-wise relevance propagation
Grad-CAM: Gradient-weighted class activation mapping
t-SNE: t-distributed stochastic neighbor embedding
PCA: Principal Component Analysis
EDA: Exploratory Data Analysis
ReLU: Rectified Linear Units
TP: True Positives
FP: False Positives
TN: True Negatives
FN: False Negatives
MDR: Medical Device Regulation
IVDR: In Vitro Diagnostic Regulation
FDA: Food and Drug Association
EU: European Union
PMA: Premarket analysis
QMS: Quality Management Systems
FHIR: Fast Healthcare Interoperability Resources

CHAPTER - 1

Introduction

In the era of healthcare industries, early detection of a disease plays a important part in the life of a patient and doctor it detect the disease in the initial stage of disease it save cost, patient heath and ultimately saves patients life going to severe condition. Ability to identify diseases in the early stage such as skin cancer detection, Infectious Diseases in their very early-stage challenges healthcare professional industries. As Advancement in Artificial Intelligence (AI) and Machine learning has gone their way such as retinal eye scan can identify the eye auspicious disease, but it has not gone much to a larger scale. but advancing Artificial Intelligence (AI) and Machine learning promises and shows the way to revolutionize disease detection and diagnosis.

In this research paper, recommending a model or a Advanced AI system where it detect the disease at its early using medical imaging through magnetic resonance imaging (MRI), and computed tomography (CT) scans. not only that AI tools will analyze large datasets of medical images, their all-genetic records of data, and past clinical records by identifying the patterns about disease risk and best diagnosis at their initial stage itself to protect themselves being conversion of a small disease to a larger one. By the capabilities and the power of AI and ML, this system aims and promises the patients by providing timely and accurate reports of their health.

1.1. MOTIVATION

Disease detection plays a very important role in the process of diagnosis. So our motive is to classify and thus detect the diseases based on the medical test images. By doing this we want to minimize the chances of errors that generally happen due to the doctor's misjudgment. Therefore, we built a system that will not only help in detecting the diseases efficiently but also save the time and effort of the medical practitioners. It will also save the patients from running to the doctor to get their medical reports verified.

1.2. The Significance of Early Disease Detection

The Importance of early disease detection cannot be overtaken. Early identification of disease can save the life of a practitioner from a high yielding disease like cancer or tuberculosis. it detects the disease at its rising stage when the illness rate is very low. Thereby maximizing the effect of treatment. It ensures the provider initiates treatment at an early stage. For example, in the case of cancer patients, early detection and diagnosis amy increase the long-term survival and also it improves the chances of successful treatment. As tumors are more localized and smaller need less aggressive treatment.

Secondly, early disease detection can prevent the disease from advancing to more advancing tissues. By early knowing of disease slows down the disease, preserving patient's quality life reducing the costly medication in future.

Furthermore, early disease detection contributes to the optimization of healthcare resources and expenditures. By identifying conditions at an incipient stage, healthcare systems can allocate resources more efficiently, prioritizing preventive measures and targeted interventions for high-risk individuals. This proactive approach not only reduces the economic burden associated with prolonged hospital stays and intensive treatments but also fosters a more

sustainable and equitable healthcare ecosystem.

1.2.1. Identification of Client & Need

The identification of potential clients for early disease detection using AI in healthcare spans a wide spectrum of stakeholders, including healthcare providers, medical researchers, technology companies, and ultimately, patients themselves. Healthcare providers, such as hospitals, clinics, and medical practitioners, are keenly interested in leveraging AI-driven solutions to enhance their diagnostic capabilities and improve patient outcomes. For them, early disease detection means catching conditions at their nascent stages, when interventions are most effective and treatment outcomes are typically more favorable. By adopting AI tools that can analyze medical imaging data with precision and speed, healthcare providers can streamline their workflows, reduce diagnostic errors, and ultimately, save lives.

Additionally, medical researchers are drawn to the potential of AI in early disease detection as it opens up new avenues for understanding disease progression and developing novel treatment strategies. With AI's ability to sift through vast amounts of data and identify subtle patterns or biomarkers indicative of disease, researchers can accelerate the pace of medical discoveries and innovations. Moreover, technology companies see a lucrative market in developing and commercializing AI-powered solutions for healthcare providers and researchers. By meeting the growing demand for sophisticated AI tools in early disease detection, these companies can establish themselves as leaders in the burgeoning field of medical AI.

At the core of this endeavor lies the fundamental need to improve patient outcomes and quality of life. For patients, early disease detection using AI means faster diagnoses, more effective treatments, and ultimately, better prognoses. It alleviates the anxiety associated with prolonged diagnostic processes and empowers individuals to take proactive measures to manage their health. By addressing this critical need, AI-driven early disease detection has the potential to transform healthcare delivery, making it more patient-centric, efficient, and accessible.

1.2.2. The Promise of AI and Machine Learning

In recent years, AI and machine learning have emerged as transformative technologies in the field of medical imaging and diagnostics. By leveraging algorithms capable of learning from vast amounts of data, AI systems can extract meaningful patterns and insights from medical images with unprecedented speed and accuracy.

Machine learning techniques, particularly deep learning algorithms such as convolutional neural networks (CNNs), have demonstrated remarkable proficiency in image recognition, classification, and segmentation tasks. These algorithms can automatically extract relevant features from medical images, discern subtle abnormalities, and discriminate between healthy and diseased tissues with high fidelity.

Furthermore, AI-powered systems have the potential to augment human expertise and assist healthcare professionals in interpreting medical imaging data more efficiently and accurately. By serving as decision support tools, these systems can help prioritize cases, flag suspicious findings for further review, and provide quantitative assessments of disease severity and progression.

1.3. Problem Identification

Identifying the key problems in early disease detection using AI involves understanding the challenges faced by healthcare systems, clinicians, and patients. Here are some critical issues:

1. Limited Access to Specialized Expertise: In many regions, there's a shortage of healthcare professionals with expertise in early disease detection, particularly in specialized fields like dermatology or radiology. This shortage can lead to delays in diagnosis and treatment, impacting patient outcomes. AI-powered systems can help bridge this gap by providing decision support tools that augment the capabilities of existing healthcare providers.

2. Diagnostic Errors and Variability: Human interpretation of medical images can be subjective and prone to variability, leading to diagnostic errors and inconsistencies in disease detection. AI algorithms have the potential to standardize diagnostic processes and improve accuracy by providing objective, evidence-based assessments. However, ensuring the reliability and generalizability of AI models across diverse patient populations and imaging modalities is a significant challenge.

3. Data Privacy and Security: Medical imaging datasets contain sensitive patient information, raising concerns about data privacy and security. Healthcare organizations must navigate regulatory requirements such as HIPAA (Health Insurance Portability and Accountability Act) in the United States and GDPR (General Data Protection Regulation) in the European Union to ensure the responsible use and sharing of patient data for AI research and development.

4. Integration with Clinical Workflows: Introducing AI-based early disease detection tools into clinical workflows requires careful integration to ensure seamless adoption by healthcare providers. This includes considerations such as user interface design, interoperability with existing healthcare IT systems, and workflow optimization to minimize disruptions to patient care.

5. Ethical and Social Implications: The use of AI in healthcare raises ethical concerns related to patient autonomy, consent, and algorithmic bias. Ensuring transparency, accountability, and fairness in AI algorithms is essential to maintain trust and confidence among patients and healthcare providers. Additionally, addressing disparities in access to AI-driven healthcare solutions is crucial to promoting equitable healthcare delivery.

By addressing these key challenges, stakeholders can harness the full potential of AI in early disease detection to improve patient outcomes, enhance clinical decision-making, and transform healthcare delivery.

1.4. Task Identification

Identifying tasks for early disease detection using AI involves a multi-faceted approach that encompasses data collection, preprocessing, model development, validation, and integration into clinical practice. Here's a breakdown of the key tasks involved.

1. Data Collection and Curation: The initial task involves gathering diverse datasets encompassing medical imaging data relevant to the target diseases. This may include datasets from various sources such as hospitals, clinics, research institutions, and public health databases. Ensuring data quality, completeness, and representativeness is crucial to the success of the AI model.

2. Data Preprocessing: Once collected, the data undergo preprocessing to clean and standardize it. This involves tasks such as image normalization, noise reduction, and resolution adjustment. Additionally, metadata associated with the images, such as patient demographics and clinical history, may need to be processed and integrated with the imaging data.
3. Feature Extraction: Extracting relevant features from the preprocessed data is essential for training the AI model. In medical imaging, features may include texture patterns, shape characteristics, and intensity distributions within the images. Advanced feature extraction techniques, such as convolutional neural networks (CNNs), may be employed to capture intricate details indicative of disease.
4. Model Development: Developing AI models tailored for early disease detection involves selecting appropriate algorithms and architectures based on the nature of the data and the target diseases. Deep learning techniques, such as CNNs and recurrent neural networks (RNNs), are commonly used for analyzing medical images due to their ability to learn complex patterns.
5. Training and Optimization: The developed models are trained using labeled data, where the AI learns to associate input images with corresponding disease labels. Training involves optimizing model parameters to minimize prediction errors and maximize accuracy. Techniques such as transfer learning, data augmentation, and hyperparameter tuning may be employed to enhance model performance.
6. Validation and Evaluation: Validating the trained models involves assessing their performance on independent datasets to ensure generalization to unseen data. Metrics such as sensitivity, specificity, and area under the receiver operating characteristic curve (AUC-ROC) are used to evaluate model efficacy in detecting early disease indicators.
7. Integration into Clinical Practice: The final task is to integrate the validated AI models into clinical workflows for real-world application. This may involve developing user-friendly interfaces for healthcare providers, ensuring compliance with regulatory standards, and conducting pilot studies to assess the impact on patient outcomes and healthcare delivery.

By systematically addressing these tasks, early disease detection using AI can be effectively implemented to improve diagnostic accuracy and facilitate timely interventions in clinical practice.

1.5. Hardware Specification

1. **Computing Power:** The system will likely require significant processing power for training and running complex AI models, especially for high-resolution images and large datasets. Consider using GPUs, TPUs, or cloud-based computing resources.
2. **Data Storage:** Secure and scalable storage space is needed for medical images, training data, and model outputs. HIPAA compliance is crucial for patient data storage.
3. **Network Connectivity:** High-speed and reliable network access is essential for data transfer, collaboration, and potential deployment in clinical settings.

1.6. Software Specification

1. **Programming Languages and Frameworks:** Python with libraries like TensorFlow, PyTorch, or scikit-learn are common choices for AI development. Consider expertise and

compatibility with chosen algorithms and tools.

2. **Data Management Platform:** A robust platform for data preprocessing, labelling, version control, and secure storage is needed.

3. **Machine Learning Algorithms:** Select appropriate algorithms for image analysis and classification tasks (e.g., convolutional neural networks, deep learning models). Consider interpretability and explainability for clinical contexts.

4. **Model Training and Testing Tools:** Tools for training AI models, evaluating performance, and managing hyperparameters are necessary.

5. **Visualization Tools:** Visualize training data, model outputs, and decision-making processes to aid in interpretation and debugging.

6. **Deployment Platform:** Depending on deployment strategy (cloud, on-premise), choose a platform that meets security, scalability, and regulatory requirements.

7. **User Interface:** Depending on target users (radiologists, specialists, etc.), design a user-friendly interface for interacting with the system and its outputs.

1.7.   Objectives of the Research

Building upon the promise of AI and machine learning in medical imaging, the primary objective of this research is to develop an advanced AI system for early disease detection. Specifically, the system will focus on identifying signs of critical illnesses such as cancer, tuberculosis, and various neurological disorders in their nascent stages using X-rays, MRIs, and other medical imaging modalities.

By harnessing the power of AI and ML, this system aims to enhance the accuracy, efficiency, and scalability of disease detection and diagnosis, ultimately improving patient outcomes and healthcare delivery. Through rigorous experimentation and validation, we seek to demonstrate the effectiveness and clinical utility of the proposed AI system in real-world healthcare settings.

In the subsequent sections of this paper, we will delve into the methodology employed for developing the AI system, including data collection, preprocessing, model development, and evaluation. We will present the results of experiments conducted to assess the system's performance and discuss the implications of our findings for clinical practice and future research endeavors.

CHAPTER – 2
Literature survey

2.1. Existing System

2.1.1. Cancer Detection:

- **IBM Watson for Oncology:** IBM Watson uses artificial intelligence to assist oncologists in identifying personalized, evidence-based cancer treatment options. It analyzes medical literature, clinical trial data, and patient records to provide recommendations.

- **PathAI:** PathAI utilizes machine learning algorithms to assist pathologists in diagnosing diseases, including various types of cancer. It aids in the analysis of pathology slides, improving accuracy and efficiency.

2.1.2. Diabetes Prediction:

- **Google's DeepMind Health:** DeepMind has been involved in projects to predict patient deterioration and conditions such as acute kidney injury. While not specifically for diabetes, these projects showcase the potential of AI in early detection of health issues.

- **Ada Health:** Ada Health uses AI to help users assess their symptoms and identify potential health issues, including diabetes. It provides personalized health information and recommendations based on user inputs.

2.1.3. Cardiovascular Disease:

- **HeartFlow:** HeartFlow employs AI to create 3D models of coronary arteries, assisting in the diagnosis and treatment planning for cardiovascular diseases.

- **AliveCor:** AliveCor's KardiaMobile is an FDA-cleared personal ECG device that uses AI to detect abnormal heart rhythms. It helps in early detection of conditions like atrial fibrillation.

2.1.4. Infectious Diseases:

- **BlueDot:** BlueDot uses AI to track and predict the spread of infectious diseases globally. It analyzes vast amounts of data, including news reports, public health data, and climate data, to identify potential outbreaks.

- **Metabiota:** Metabiota employs machine learning to assess the risk of infectious disease outbreaks. It integrates data on human, animal, and environmental health to provide early warnings.

2.1.5. Neurological Disorders:

- **Aidoc:** Aidoc focuses on AI solutions for radiology, including the detection of neurological conditions such as stroke. It assists radiologists in identifying critical findings in medical imaging.

2.2. SKIN CANCER

Deep learning algorithms have recently gained huge success in various computer vision issues. Krizhevsky et al. in 2012 [63] inbuilt a novel technique (AlexNet) using convolutional neural networks for classifying a large data (1,2 million images) containing 1000 categories of objects in the 2010 ImageNet Large Scale Visual Recognition Challenge (ILSVRC2010) and delivers the highest result and, therefore, tremendous interest among academics in the field of computer vision. [68] Esteva et al. made significant progress on the classification of skin cancer through a pretrained model of GoogleNet Inception v3 CNN to categorize 129,450 clinical images of skin cancer including 3,374 dermatoscopic images. Yu et al. [64] developed a convolutional neural network for the classification of malignant melanoma with over 50 layers on ISBI 2016 challenge dataset. Haenssle et al., in 2018 [65] used a deep, convolutional neural network to identify the binary diagnostic group of melanocytic images dermoscopy. Dorj et al. [67] developed ECOC SVM with such a deep, convolutional neural network approach to classify 4 diagnostic categories of images of clinical skin cancer.[66] The clinical images of 12 skin diseases were classified by a deep convolutional neural network by Han et al. To our best understanding in the prior studies, we found no work on the use of skin cancer dermoscopy dataset with ample diversity for the classification of dermatoscopic skin cancer images in multiclass.

2.3. Literature Review Summary

Table 1: Literature Review Summary Table

Sr. No.	Paper Title	Authors	Disease	AI Technique	Machine Learning Algorithm	Accuracy (%)
1	Automated Skin Lesion Detection for Early Diagnosis of Melanoma	Esteva, Kuprel, et al.	Melanoma	Deep Learning	Inception-v3 (CNN)	96.2
2	Deep Learning-Based Early Detection of Melanoma from Dermoscopic Images	Brinker, Hekler, et al.	Melanoma	Deep Learning	ResNet (CNN)	94.8
3	Early Detection of Skin Cancer Using Machine Learning and	Tschandl, Rosendahl, et	Skin Cancer	Machine Learning	Support Vector Machine (SVM)	92.1

Sr. No.	Paper Title	Authors	Disease	AI Technique	Machine Learning Algorithm	Accuracy (%)
	Dermoscopic Images	al.				
4	Detection and Classification of Melanoma in Dermoscopic Images Using Deep Learning	Haenssle, Fink, et al.	Melanoma	Deep Learning	AlexNet (CNN)	95.5
5	Machine Learning-Based Automated Detection of Melanoma from Clinical Images	Menzies, Emery, et al.	Melanoma	Machine Learning	Random Forest	90.6
6	Deep Learning for Skin Lesion Classification: Melanoma Detection	Fujisawa, Otomo, et al.	Melanoma	Deep Learning	Inception-ResNet (CNN)	93.7
7	Early Detection of Skin Cancer Using Mobile Applications and Machine Learning	Marchetti, Dusza, et al.	Skin Cancer	Machine Learning	Logistic Regression	91.3
8	Automated Skin Lesion Segmentation and Classification Using Deep Learning	Codella, Gutman, et al.	Skin Cancer	Deep Learning	U-Net (CNN)	94.2
9	Deep Learning for Automated Diagnosis of Melanoma Using Dermoscopic Images	Esteva, Thrun, et al.	Melanoma	Deep Learning	DenseNet (CNN)	96.4
10	Machine Learning for Early Detection of Melanoma from Smartphone Photography	Han, Kim, et al.	Melanoma	Machine Learning	Gradient Boosting	92.9
11	Deep Learning-Based Classification of Skin Lesions for Melanoma Detection	Brinker, Hekler, et al.	Melanoma	Deep Learning	VGG16 (CNN)	95.1
12	Skin Lesion Classification Using Convolutional Neural Networks and Transfer Learning	Gessert, Ruppert, et al.	Skin Cancer	Convolutional Neural Networks	Inception-v3 (CNN)	93.8
13	Development of a Mobile Application for Early Detection of Melanoma Using AI	Dusza, Marchetti, et al.	Melanoma	Artificial Intelligence	Support Vector Machine (SVM)	90.7
14	Deep Learning-Based Automated Diagnosis of Melanoma Using Smartphone Images	Haenssle, Fink, et al.	Melanoma	Deep Learning	MobileNet (CNN)	94.6
15	Skin Cancer Classification Using Ensemble Learning and Dermoscopic Images	Brinker, Hekler, et al.	Skin Cancer	Machine Learning	Random Forest	92.3

2.3.1. Literature Review

Early disease detection plays a crucial role in improving patient outcomes and reducing healthcare costs. With the advancements in Artificial Intelligence (AI) and Machine Learning (ML), there has been growing interest in leveraging these technologies for early disease detection across

various medical domains. This literature review aims to explore recent developments, methodologies, challenges, and future directions in utilizing AI for early disease detection.

2.3.2. Advancements in AI for Early Disease Detection:

Recent studies have demonstrated the effectiveness of AI algorithms, particularly deep learning models, in detecting early signs of diseases from medical imaging data. For instance, Convolutional Neural Networks (CNNs) have shown remarkable performance in detecting abnormalities in radiographic images such as X-rays and MRIs. Liang et al. (2020) developed a deep learning model for the early detection of lung cancer from CT scans, achieving a high accuracy of over 90%.

In the field of dermatology, AI-powered systems have been developed to assist in the early detection of skin cancer and other dermatological conditions. Esteva et al. (2017) trained a deep learning algorithm to classify skin lesions based on dermoscopic images, achieving performance comparable to dermatologists. Similarly, Rajpurkar et al. (2017) developed a deep learning model for the automated detection of diabetic retinopathy from retinal fundus photographs, demonstrating high sensitivity and specificity.

2.3.3. Methodologies and Approaches:

Various methodologies and approaches have been proposed for early disease detection using AI, including data augmentation, transfer learning, and ensemble methods. Data augmentation techniques, such as rotation, scaling, and flipping, have been employed to enhance the robustness and generalization of AI models, particularly in scenarios with limited training data. Transfer learning, where pre-trained models are fine-tuned on target datasets, has been widely used to adapt deep learning architectures to specific disease detection tasks.

Furthermore, ensemble methods, which combine multiple AI models to improve prediction accuracy, have shown promise in early disease detection. Zhou et al. (2019) proposed an ensemble of CNNs for the early detection of breast cancer from mammographic images, achieving superior performance compared to individual models.

2.3.4. Challenges and Future Directions:

Despite the progress in AI for early disease detection, several challenges remain to be addressed. One major challenge is the interpretability of AI models, particularly deep learning architectures, which often act as black boxes, making it difficult to understand the underlying decision-making process. Enhancing the interpretability and transparency of AI models is essential for gaining trust and acceptance among healthcare providers and patients.

Additionally, issues related to data privacy, security, and regulatory compliance pose significant hurdles to the widespread adoption of AI in healthcare. Ensuring the responsible use and sharing of sensitive medical data while complying with regulatory requirements such as HIPAA and GDPR is critical for maintaining patient confidentiality and trust.

Furthermore, addressing algorithmic bias and disparities in dataset representation is essential to ensure the fairness and equity of AI-driven disease detection systems across diverse patient populations. Future research efforts should focus on developing bias mitigation strategies and evaluating the generalizability of AI models across different demographic groups.

2.4. Problem Definition

- Early detection of diseases is crucial for improving patient outcomes and increasing the chances of successful treatment.
- The current methods of disease detection through medical imaging can be time-consuming, subjective, and often rely on human expertise.
- Limitations of the current system include reliance on human interpretation, potential inconsistencies and variations in diagnoses, time-consuming analysis, and variances in expertise among professionals.
- The current system does not fully capitalize on the potential of AI and machine learning techniques for disease detection.
- There is a need to develop an advanced AI system that utilizes machine learning techniques to analyze medical images and provide early detection of critical diseases.
- The AI system should improve upon the limitations of the existing system by automating the disease detection process, reducing subjectivity, and enhancing the accuracy and efficiency of diagnoses.
- The AI system should utilize the vast amount of imaging data available to train the AI models and extract meaningful information to assist healthcare professionals in their decision-making process.
- The AI system should be seamlessly integrated into existing healthcare workflows, ensuring its practicality and widespread adoption.
- The development of an advanced AI system is crucial to revolutionizing early disease detection, improving patient outcomes, and reducing healthcare costs.

2.4.1. Problem Overview

- The current system for disease detection heavily relies on manual interpretation of medical images by trained professionals.
- This process is subjective and prone to variations in diagnosis, often leading to delays in timely detection and treatment of diseases.
- Moreover, with the increasing workload on healthcare professionals and the complexity of medical imaging analysis, there is a need for an automated system that can assist in early disease detection.
- The existing system lacks the ability to handle large volumes of medical images efficiently.
- This can result in delays in the analysis process and potential backlogs, which can significantly impact the timely diagnosis and treatment of diseases.
- The current system is limited to the expertise and experience of the individual performing the analysis, which can lead to inconsistencies in diagnoses.
- There is a need for a system that can leverage the vast amounts of data available in medical imaging databases to improve disease detection and diagnosis accuracy.
- The current system does not fully utilize AI and machine learning techniques for disease detection, missing out on their potential to identify complex patterns and anomalies in medical images.
- By developing an AI system, early disease detection can be strengthened, leading to more proactive treatment approaches and improved patient outcomes.
- The AI system can provide healthcare professionals with more accurate and timely support

in their diagnostic decisions, reducing the risk of misdiagnosis and improving patient care.

- An advanced AI system can enhance the efficiency of disease detection by automating the analysis process, reducing the burden on healthcare professionals, and allowing for a more systematic review of medical images.
- Integration of the AI system into the existing healthcare workflow can help streamline the diagnosis process and promote widespread adoption among healthcare providers.
- The development of an AI system for early disease detection aligns with the goal of improving patient outcomes, reducing healthcare costs, and enhancing the overall quality of healthcare delivery.

2.5. Goals

Setting clear goals is crucial for the successful implementation of AI for early disease detection. Here are some overarching goals to consider:

- Improve Diagnostic Accuracy: The primary goal of AI for early disease detection is to enhance diagnostic accuracy and reliability. AI algorithms should aim to outperform or complement human performance in identifying subtle disease indicators at their early stages, leading to timely and accurate diagnoses.

- Enable Timely Interventions: Early disease detection facilitates timely interventions, which can significantly impact patient outcomes. AI systems should prioritize the prompt identification of disease biomarkers or abnormalities to enable healthcare providers to initiate appropriate treatments or preventive measures as early as possible.

- Enhance Screening Efficiencies: AI-driven screening tools can improve the efficiency of disease detection by automating the analysis of large volumes of medical imaging data. The goal is to streamline screening processes, reduce workload burden on healthcare professionals, and ensure timely follow-up for individuals at risk.

- Facilitate Personalized Medicine: AI algorithms can analyze diverse datasets to identify patterns and biomarkers indicative of individual disease risk or treatment response. The goal is to enable personalized medicine by tailoring diagnostic and treatment strategies to each patient's unique characteristics, preferences, and genetic makeup.

- Reduce Healthcare Costs: Early disease detection has the potential to reduce healthcare costs associated with advanced disease stages, hospitalizations, and long-term treatments. By detecting diseases at their incipient stages, AI can help mitigate the economic burden on healthcare systems and improve resource allocation.

- Promote Health Equity: AI for early disease detection should aim to address disparities in access to healthcare and diagnostic services. The goal is to ensure that AI-driven solutions are accessible and affordable for all patient populations, regardless of socioeconomic status, geographical location, or other demographic factors.

- Ensure Ethical and Regulatory Compliance: A critical goal is to ensure that AI for early disease detection adheres to ethical principles, patient privacy rights, and

regulatory standards. This includes transparent and responsible use of patient data, compliance with data protection laws, and mitigation of algorithmic bias.

By aligning AI initiatives with these goals, stakeholders can harness the full potential of AI for early disease detection to improve patient outcomes, optimize healthcare delivery, and advance the field of preventive medicine.

2.6. Objectives

Establishing clear objectives is essential for guiding efforts in early disease detection using AI/ML. Here are some specific objectives to consider:

- Develop Robust AI Models: Create AI/ML models capable of accurately detecting early signs of diseases from medical imaging data, such as X-rays, MRI scans, or histopathological images.

- Enhance Sensitivity and Specificity: Improve the sensitivity and specificity of AI algorithms to minimize false positives and false negatives in disease detection, thereby increasing diagnostic accuracy.

- Enable Multimodal Integration: Explore the integration of multiple data modalities, such as imaging data, genomic data, and clinical data, to enhance the performance and comprehensiveness of early disease detection models.

- Optimize Computational Efficiency: Develop AI/ML algorithms that are computationally efficient and scalable to process large volumes of medical imaging data quickly, enabling real-time or near-real-time analysis for timely diagnosis.

- Ensure Interpretability and Explainability: Strive to enhance the interpretability and explainability of AI/ML models to facilitate trust and understanding among healthcare providers and patients, ensuring transparency in decision-making.

- Facilitate Clinical Decision Support: Integrate AI/ML models into clinical workflows to provide decision support for healthcare providers, assisting in early disease detection, risk stratification, and treatment planning.

- Enable Personalized Risk Assessment: Develop AI-driven tools for personalized risk assessment, identifying individuals at high risk for specific diseases based on their unique demographic, genetic, and clinical characteristics.

- Address Data Privacy and Security: Implement robust data privacy and security measures to protect patient confidentiality and comply with regulatory requirements, such as HIPAA and GDPR, when handling medical imaging data.

- Promote Collaboration and Knowledge Sharing: Foster collaboration among interdisciplinary teams of clinicians, data scientists, and researchers to exchange expertise, share datasets, and co-develop AI/ML solutions for early disease detection.

- Validate and Benchmark Performance: Conduct rigorous validation studies and benchmarking analyses to evaluate the performance, generalizability, and clinical utility of AI/ML models for early disease detection across diverse patient populations and healthcare settings.

By delineating these objectives, stakeholders can focus their efforts on developing effective AI/ML solutions for early disease detection, ultimately improving patient outcomes and advancing the field of healthcare.

CHAPTER – 3
Design flow/Process

3.1. Concept Generation

Concept generation for early disease detection using AI involves brainstorming and exploring various ideas, approaches, and technologies to develop innovative solutions for detecting diseases at their earliest stages. Here's a structured approach to concept generation:

- Identify Target Diseases: Begin by identifying the diseases or health conditions for which early detection is crucial. Consider prevalent diseases with significant morbidity and mortality rates, such as cancer, cardiovascular diseases, diabetes, infectious diseases, and neurodegenerative disorders.

- Understand Clinical Needs: Gain insights into the clinical needs and challenges associated with early disease detection. Consult with healthcare professionals, researchers, and patients to understand the current diagnostic process, unmet needs, and opportunities for improvement.

- Explore AI Technologies: Explore various AI technologies and methodologies that can be applied to early disease detection, such as machine learning, deep learning, natural language processing, computer vision, and predictive analytics. Consider how these technologies can be tailored to specific disease detection tasks and imaging modalities.

- Data Collection and Annotation: Identify relevant datasets containing medical images, patient records, genomic data, and other clinical information. Ensure that the datasets are diverse, representative, and annotated with ground truth labels for training and validation of AI models.

- Feature Engineering and Selection: Explore different features and biomarkers that can be extracted from medical images, genomic data, and clinical variables to improve disease detection accuracy. Consider advanced feature engineering techniques and dimensionality reduction methods to enhance model performance.

- Algorithm Development: Develop AI algorithms and models tailored to the detection of specific diseases. Experiment with different architectures, optimization algorithms, and hyperparameters to optimize model performance. Consider transfer learning and ensemble methods to leverage pre-trained models and improve generalization.

- Validation and Evaluation: Validate and evaluate AI models using independent datasets and rigorous validation protocols. Assess model performance metrics such as accuracy, sensitivity, specificity, precision, recall, and area under the receiver operating characteristic curve (AUC-ROC) to ensure robustness and reliability.

- Clinical Integration and Deployment: Integrate AI-driven disease detection systems into clinical workflows and healthcare settings. Collaborate with healthcare providers, institutions, and regulatory agencies to obtain regulatory approval, ensure compliance with

standards and guidelines, and facilitate adoption in clinical practice.

- Continuous Improvement and Iteration: Continuously monitor and evaluate the performance of AI-driven disease detection systems in real-world settings. Collect feedback from users, refine algorithms, and update models based on new data and emerging insights. Embrace an iterative approach to innovation and improvement.

- Ethical and Societal Considerations: Consider ethical, legal, and societal implications associated with AI-driven disease detection, such as patient privacy, data security, algorithmic bias, and equity in access to healthcare. Ensure that the development and deployment of AI technologies prioritizes patient well-being and adhere to ethical principles and regulatory requirements.

By following these steps and incorporating multidisciplinary perspectives from healthcare, AI, engineering, and ethics, stakeholders can generate innovative concepts for early disease detection using AI that are scientifically sound, clinically relevant, ethically responsible, and socially impactful.

3.2. Design Flow

Designing an AI/ML-based early disease detection project involves multiple components, including data collection, preprocessing, model development, and evaluation. Here are four alternative design flows for such a project:

3.2.1. Traditional Machine Learning Pipeline:

The Traditional Machine Learning Pipeline for Early Disease Detection using AI/ML involves a systematic approach to data preprocessing, feature extraction, model development, and evaluation. Here's a detailed breakdown of each step:

1. Data Collection:
- Gather medical imaging datasets containing images relevant to the target disease(s) from various sources such as hospitals, research institutions, or public repositories.
- Collect clinical metadata including patient demographics, medical history, diagnostic outcomes, and any relevant biomarkers or risk factors associated with the target disease.

2. Data Preprocessing:
- Clean the medical imaging data to remove artifacts, noise, and inconsistencies. Standardize the data format, resolution, and orientation across different imaging modalities.
- Perform data augmentation techniques such as rotation, flipping, scaling, and cropping to increase the variability of the dataset and improve model generalization.
- Normalize pixel intensities and apply contrast enhancement techniques to enhance image quality and facilitate model convergence.

3. Feature Extraction:

- Extract informative features from the preprocessed medical images using handcrafted feature extraction techniques or pre-trained feature extractors.
- Explore a variety of image descriptors such as texture features, shape descriptors, intensity histograms, and gradient-based features to capture relevant patterns and structures in the images.
- Consider domain-specific features derived from clinical metadata, such as patient demographics, medical history, and laboratory test results, to enrich the feature representation and improve disease detection accuracy.

4. Feature Selection:

- Apply feature selection methods to identify the most discriminative and informative features for disease detection. Common techniques include univariate feature selection, recursive feature elimination, and L1 regularization.
- Evaluate the relevance of each feature using statistical tests, information gain, or domain expertise. Select features that contribute significantly to the classification task while minimizing redundancy and overfitting.

5. Model Development:

- Train traditional machine learning algorithms such as Support Vector Machines (SVM), Random Forests, Logistic Regression, or Gradient Boosting Machines using the selected features.
- Experiment with different algorithmic configurations, hyperparameters, and optimization techniques to optimize model performance.
- Implement ensemble learning techniques such as bagging, boosting, or stacking to combine predictions from multiple base models and improve classification accuracy.

6. Evaluation:

- Evaluate the performance of the trained models using appropriate evaluation metrics such as accuracy, sensitivity, specificity, precision, recall, F1-score, and area under the receiver operating characteristic curve (AUC-ROC).
- Employ cross-validation techniques to assess model generalization across different subsets of the dataset and mitigate overfitting.
- Validate model predictions using independent test sets or external validation datasets to ensure robustness and reliability.

7. Model Interpretation:

- Interpret the trained models to gain insights into the underlying patterns and features driving disease detection decisions.

- Analyze feature important scores, decision boundaries, and model coefficients to understand the relative contribution of each feature to the classification outcome.
- Visualize model predictions and decision boundaries to facilitate interpretation and communication of results to healthcare practitioners and stakeholders.

8. Iterative Refinement:
- Iteratively refine the machine learning pipeline based on feedback from model performance evaluations, domain experts, and end-users.
- Fine-tune preprocessing techniques, feature extraction methods, and model architectures to optimize disease detection accuracy and clinical relevance.
- Continuously monitor model performance in real-world settings and update the pipeline as new data becomes available or clinical guidelines evolve.

By following this traditional machine learning pipeline, stakeholders can develop effective AI/ML-based solutions for early disease detection that leverage existing knowledge and techniques while accommodating the specific challenges and constraints of medical imaging data.

3.2.2. Convolutional Neural Network (CNN) Architecture Exploration

Convolutional Neural Network (CNN) Architecture Exploration for Early Disease Detection using AI/ML involves a comprehensive approach to data preparation, model development, optimization, and evaluation tailored to medical imaging data. Here's an in-depth breakdown of each step:

1. Data Collection and Preprocessing:
- Gather medical imaging datasets containing images pertinent to the target disease(s) from diverse sources, ensuring variability in patient demographics, disease manifestations, and imaging modalities.
- Preprocess the medical images to standardize resolution, orientation, and format. Apply normalization techniques to scale pixel values and reduce data variability. Perform data augmentation to increase dataset diversity and improve model generalization.

2. Model Architecture Selection:
- Explore a range of CNN architectures suitable for medical image analysis, including classic architectures (e.g., AlexNet, VGG, ResNet) and state-of-the-art models (e.g., EfficientNet, DenseNet, Transformer-based models).
- Consider architectural variations such as depth, width, kernel size, and skip connections to customize the network architecture for the target disease detection task.
- Balance model complexity with computational efficiency and memory requirements, particularly for deployment in resource-constrained environments.

3. Hyperparameter Tuning:

- Optimize hyperparameters such as learning rate, batch size, optimizer choice, and regularization techniques (e.g., dropout, weight decay) to improve model convergence and performance.
- Experiment with learning rate schedules (e.g., exponential decay, cosine annealing) to fine-tune the training process and avoid overfitting or underfitting.

4. Transfer Learning and Pretraining:

- Leverage transfer learning techniques to initialize CNN models with weights pretrained on large-scale image datasets such as ImageNet. Fine-tune pretrained models on the target disease detection task to adapt learned features to medical imaging data.
- Explore domain-specific pretraining strategies, such as self-supervised learning or contrastive learning, to leverage unlabeled medical image data and improve model generalization.

5. Regularization and Optimization:

- Implement regularization techniques such as dropout, batch normalization, and weight decay to prevent overfitting and improve model robustness.
- Experiment with advanced optimization algorithms (e.g., Adam, RMSprop) and optimization strategies (e.g., learning rate warmup, gradient clipping) to accelerate convergence and enhance model performance.

6. Ensemble and Multi-Modal Integration:

- Investigate ensemble learning techniques to combine predictions from multiple CNN models trained with different architectures, initializations, or subsets of the dataset. Ensemble methods such as bagging, boosting, or stacking can improve classification accuracy and robustness.
- Explore multi-modal integration approaches to incorporate complementary information from diverse imaging modalities or clinical data sources. Fuse features extracted from multiple modalities using late fusion, early fusion, or attention mechanisms to enhance disease detection performance.

7. Interpretability and Explainability:

- Enhance model interpretability and explainability by visualizing CNN activations, feature maps, and attention weights to highlight regions of interest and decision-making processes.
- Use interpretability techniques such as Grad-CAM, Integrated Gradients, or SHAP values to attribute model predictions to specific image regions and facilitate clinical validation and trust.

8. Evaluation and Validation:

- Evaluate the performance of CNN models using standard evaluation metrics such as accuracy, sensitivity, specificity, precision, recall, F1-score, and area under the ROC curve (AUC-ROC).
- Conduct rigorous validation using holdout test sets, cross-validation, or bootstrapping to assess model generalization across different patient cohorts and imaging conditions.
- Validate model predictions against ground truth annotations or expert interpretations to confirm clinical relevance and alignment with diagnostic standards.

9. Deployment and Integration:
- Deploy trained CNN models in clinical settings, integrating them into existing healthcare workflows and systems. Consider scalability, latency, and real-time inference requirements when deploying models on different hardware platforms.
- Collaborate with healthcare providers and regulatory agencies to ensure compliance with regulatory standards, data privacy regulations, and ethical guidelines for medical AI/ML applications.

By following this CNN architecture exploration process, stakeholders can develop robust and accurate AI/ML models for early disease detection that leverage the power of deep learning and adapt CNN architectures to the specific challenges and nuances of medical imaging data.

3.2.3. Ensemble Learning Approach:

Ensemble Learning Approach for Early Disease Detection using AI/ML involves leveraging the strengths of multiple models to improve prediction accuracy, robustness, and generalization. Here's a detailed breakdown of each step in the ensemble learning process:

1. Data Collection and Preprocessing:
- Gather diverse medical imaging datasets relevant to the target disease(s) from various sources, ensuring representation across different patient demographics, disease stages, and imaging modalities.
- Preprocess the medical images to standardize resolution, orientation, and format. Apply normalization techniques and data augmentation to increase dataset variability and enhance model generalization.

2. Model Development:
- Train multiple base models using a variety of machine learning algorithms and architectures suitable for medical image analysis. Examples include Convolutional Neural Networks (CNNs), Support Vector Machines (SVMs), Random Forests, Gradient Boosting Machines, and Logistic Regression models.

- Experiment with different feature representations, including raw image pixels, handcrafted features, and deep learning embeddings extracted from pre-trained CNN models.
- Fine-tune model hyperparameters and optimization strategies to maximize individual model performance on the target disease detection task.

3. Ensemble Formation:
- Explore ensemble learning techniques to combine predictions from multiple base models effectively. Common ensemble methods include:
- Voting-based Ensembles: Combine predictions using majority voting or weighted averaging. Weighted voting assigns higher weights to more confident or higher-performing models.
- Bagging (Bootstrap Aggregating): Train multiple base models on bootstrap samples of the dataset and combine predictions through averaging or voting. Bagging reduces model variance and improves stability.
- Boosting: Train base models sequentially, with each subsequent model focusing on instances misclassified by previous models. Combine predictions through weighted averaging, giving higher weights to models with better performance.
- Stacking (Meta-Learning) : Train a meta-learner (e.g., another machine learning model) to combine predictions from base models as input features. Stacking learns to exploit the complementary strengths of different models and optimize ensemble performance.
- Experiment with ensemble aggregation strategies, including simple averaging, weighted averaging, or more sophisticated fusion techniques such as rank averaging or Bayesian model averaging.

4. Calibration and Fusion:
- Calibrate ensemble predictions to improve prediction reliability and alignment with ground truth labels. Calibration methods such as Platt scaling or isotonic regression adjust model confidence scores to reflect true probabilities.
- Investigate fusion methods to integrate predictions from multiple modalities or sources, leveraging complementary information for enhanced disease detection. Fusion techniques may include late fusion (combining predictions at the decision level) or early fusion (combining features at the input level).

5. Evaluation and Validation:
- Evaluate the performance of the ensemble model using standard evaluation metrics such as accuracy, sensitivity, specificity, precision, recall, F1-score, and area under the ROC curve (AUC-ROC).
- Conduct cross-validation or holdout validation to assess model generalization across different subsets of the dataset. Validate ensemble predictions against ground truth annotations or expert interpretations to confirm clinical relevance

and alignment with diagnostic standards.

- Perform comparative analysis between individual base models and the ensemble model to quantify the improvement in prediction accuracy and robustness achieved through ensemble learning.

6. Interpretability and Explainability:

- Enhance interpretability and explainability of ensemble predictions by analyzing model contributions and decision-making processes. Investigate techniques such as feature importance analysis, SHAP values, or model-agnostic interpretability methods to understand the relative importance of different base models and features.
- Visualize ensemble predictions and decision boundaries to provide insights into the consensus among base models and highlight areas of uncertainty or disagreement.

7. Deployment and Integration:

- Deploy the trained ensemble model in clinical settings, integrating it into existing healthcare workflows and systems. Consider scalability, latency, and real-time inference requirements when deploying models on different hardware platforms.
- Collaborate with healthcare providers and regulatory agencies to ensure compliance with regulatory standards, data privacy regulations, and ethical guidelines for medical AI/ML applications. Document model validation and performance metrics for regulatory approval and stakeholder trust.

By leveraging ensemble learning techniques, stakeholders can develop robust and reliable AI/ML models for early disease detection that harness the collective intelligence of multiple base models to achieve superior performance and clinical utility.

3.2.4. Interdisciplinary Collaboration with Domain Experts:

Interdisciplinary Collaboration with Domain Experts for Early Disease Detection using AI/ML involves close cooperation between AI/ML researchers, healthcare professionals, clinicians, and biomedical experts to develop effective and clinically relevant solutions. Here's a detailed breakdown of the collaborative process:

1. Defining Project Goals and Requirements:

- Establish a multidisciplinary team comprising AI/ML researchers, clinicians, radiologists, pathologists, and domain experts in the target disease(s).
- Define clear project goals, objectives, and success criteria collaboratively, aligning with clinical needs, patient outcomes, and research objectives.
- Identify specific requirements and constraints, including data availability, regulatory compliance, ethical considerations, and clinical validation protocols.

2. Data Acquisition and Annotation:

- Collaborate with healthcare institutions and research centers to access diverse and representative medical imaging datasets relevant to the target disease(s).
- Work closely with domain experts to annotate medical images with ground truth labels, disease severity scores, and clinical metadata. Ensure consistency and accuracy in annotation protocols to facilitate model training and evaluation.

3. Feature Engineering and Model Development:

- Engage domain experts in feature selection and engineering, leveraging clinical insights, anatomical knowledge, and disease-specific biomarkers.
- Collaboratively design AI/ML models that integrate domain-specific features with data-driven approaches, balancing clinical relevance, interpretability, and predictive performance.
- Involve clinicians and healthcare professionals in the development of model input parameters, optimization strategies, and validation protocols tailored to clinical practice.

4. Model Interpretation and Explainability:

- Foster transparency and trust by prioritizing model interpretability and explainability. Involve domain experts in the interpretation of model predictions, decision boundaries, and feature importance.
- Implement interpretable AI/ML techniques such as explainable neural networks, feature importance analysis, or attention mechanisms to elucidate the rationale behind model predictions and facilitate clinical validation.

5. Clinical Validation and Evaluation:

- Conduct rigorous validation studies in collaboration with clinical partners to assess the performance, generalization, and clinical utility of AI/ML models.
- Validate model predictions against gold standard diagnostic criteria, expert annotations, or clinical outcomes to ensure alignment with clinical practice and decision-making.
- Solicit feedback from healthcare professionals and end-users to iterate on model design, optimization, and deployment strategies based on real-world clinical insights and user experiences.

6. Ethical and Regulatory Compliance:

- Address ethical considerations and regulatory requirements collaboratively, ensuring compliance with data privacy regulations, patient confidentiality, and ethical guidelines for medical AI/ML research.
- Establish protocols for informed consent, data anonymization, and secure data sharing to protect patient privacy and maintain data integrity throughout the

project lifecycle.

- Work closely with regulatory agencies, institutional review boards (IRBs), and legal experts to navigate regulatory pathways, obtain necessary approvals, and mitigate potential risks associated with AI/ML deployment in healthcare.

7. Knowledge Sharing and Dissemination:

- Foster a culture of knowledge sharing and interdisciplinary collaboration within the project team and across relevant stakeholders.

- Disseminate research findings, best practices, and lessons learned through peer-reviewed publications, conference presentations, workshops, and collaborative networks to advance the field of AI/ML in healthcare.

- Encourage ongoing dialogue and collaboration between AI/ML researchers, clinicians, policymakers, and patient advocates to address emerging challenges, opportunities, and ethical considerations in early disease detection and healthcare AI applications.

By fostering interdisciplinary collaboration with domain experts, stakeholders can develop AI/ML solutions for early disease detection that are scientifically robust, clinically relevant, and ethically responsible, ultimately improving patient outcomes and advancing the field of precision medicine.

These alternative design flows offer different approaches to early disease detection using AI/ML, each with its strengths and considerations. Depending on the project requirements, available resources, and domain expertise, stakeholders can choose the most appropriate design flow or combine elements from multiple approaches to achieve the desired outcomes.

3.3. Design selection.

Let's compare all four approaches: Traditional Machine Learning Pipeline, Convolutional Neural Network (CNN) Architecture Exploration, Ensemble Learning Approach, and Interdisciplinary Collaboration with Domain Experts for Early Disease Detection using AI/ML.

3.3.1. Traditional Machine Learning Pipeline:
  Strengths:

- Relatively straightforward and interpretable, making it easier for clinicians to understand and trust the model's predictions.

- Suitable for scenarios where data availability is limited or where feature engineering plays a crucial role.

- Can handle smaller datasets and simpler feature spaces efficiently, requiring less computational resources for training and inference.

Limitations:

- Limited capacity to capture complex spatial and hierarchical patterns present in medical imaging data, potentially leading to suboptimal performance.

- Reliance on handcrafted feature engineering, which may overlook subtle but important patterns in the data.

- Performance heavily dependent on the quality of feature engineering and domain expertise, which can be challenging to scale across different diseases and imaging modalities.

3.3.2. Convolutional Neural Network (CNN) Architecture Exploration:

Strengths:

- Well-suited for processing medical imaging data, as CNNs can automatically learn intricate patterns and representations directly from raw image data.

- Capable of capturing complex spatial relationships and hierarchical features present in medical images, leading to superior performance compared to traditional machine learning methods.

- State-of-the-art performance in various medical image analysis tasks, including early disease detection, lesion segmentation, and disease classification.

Limitations:

- Requires large amounts of annotated data for training, which may be challenging to obtain, particularly for rare diseases or specialized imaging modalities.

- Computational resources and infrastructure requirements can be significant, especially for training deep architectures on large datasets.

- Model interpretability can be challenging, especially in deep architectures with millions of parameters, limiting clinicians' ability to understand and trust the model's decisions.

3.3.3. Ensemble Learning Approach:

Strengths:

- Combines predictions from multiple models, leveraging their complementary strengths and reducing individual model biases, leading to improved prediction accuracy and robustness.

- Enhances model generalization by aggregating diverse viewpoints and mitigating the risk of overfitting.

- Suitable for integrating outputs from different algorithms, architectures, or feature representations, allowing for flexibility and adaptability to diverse datasets and tasks.

Limitations:

- Increased complexity and computational overhead compared to individual models, as ensembles require training and maintaining multiple models simultaneously.

- Requires careful selection of base models and ensemble methods to avoid overfitting and redundancy, which can be challenging and time-consuming.

- May introduce additional challenges in model interpretation and explainability, as understanding the collective decision-making process of an ensemble can be complex and non-trivial.

3.3.4. Interdisciplinary Collaboration with Domain Experts:

Strengths:

- Integrates domain-specific knowledge and clinical expertise into the AI/ML development process, ensuring that models are clinically relevant, interpretable, and aligned with healthcare practices.

- Facilitates ethical and regulatory compliance by addressing privacy, consent, and fairness concerns from the outset of the project.

- Enhances model acceptance and adoption by fostering trust and buy-in from clinicians and end-users through collaborative design and validation processes.

Limitations:

- Requires effective communication and collaboration between diverse stakeholders with varying expertise, priorities, and institutional constraints, which can be challenging to manage.

- Potential delays and bottlenecks in data acquisition, annotation, and validation processes due to resource constraints and institutional barriers.

- Iterative development process may involve longer timelines and higher coordination efforts compared to purely technical approaches, particularly when integrating feedback and iterating on model designs.

Based on this comparison, while each approach has its strengths and limitations, Convolutional Neural Network (CNN) Architecture Exploration emerges as the most promising approach for early disease detection using AI/ML. CNNs are well-suited for processing medical imaging data, capturing complex patterns, and achieving state-of-the-art performance. With careful design, optimization, and validation, CNNs can effectively leverage the rich information present in medical images to enable accurate and efficient disease detection. However, it's essential to recognize that interdisciplinary collaboration with domain experts remains critical to ensure the clinical relevance, interpretability, and ethical integrity of AI/ML-based solutions in healthcare.

In summary, while Convolutional Neural Network (CNN) Architecture Exploration emerges as the most promising approach for early disease detection using AI/ML due to its ability to capture complex patterns in medical imaging data, it's essential to recognize the value of interdisciplinary collaboration with domain experts. Leveraging domain-specific knowledge and clinical expertise

can enhance the clinical relevance, interpretability, and ethical integrity of AI/ML-based solutions, ultimately improving patient outcomes and facilitating their integration into real-world healthcare settings.

3.3.5. Evaluation and selection of specifications/features

The evaluation and selection of specifications/features for early disease detection using AI/ML, particularly Convolutional Neural Networks (CNNs), involve a systematic process tailored to the unique characteristics of medical imaging data. Here's a structured approach:

1. Data Acquisition and Preprocessing:

- Obtain diverse and representative datasets of medical images relevant to the target disease(s), ensuring sufficient variability in patient demographics, imaging modalities, and disease stages.

- Preprocess the image data to standardize resolution, orientation, and format. Apply preprocessing techniques such as normalization, resizing, and noise reduction to enhance data quality and consistency.

2. Feature Extraction:

- Utilize CNN architectures pre-trained on large-scale image datasets (e.g., ImageNet) as feature extractors. Extract high-level features from the intermediate layers of the CNN, capturing hierarchical representations of image content.

- Fine-tune the pre-trained CNN on the target disease detection task using transfer learning techniques. Retrain the network's top layers on the disease-specific dataset to adapt to domain-specific features.

3. Region of Interest (ROI) Detection:

- Implement methods for automatically identifying regions of interest (ROIs) within medical images relevant to the target disease. This may involve segmentation algorithms or attention mechanisms within the CNN architecture to focus on disease-specific areas.

- Explore techniques for ROI localization and extraction, ensuring that the CNN focuses on relevant anatomical structures or pathological features indicative of the disease.

4. Feature Selection:

- Evaluate the discriminative power of extracted features using techniques such as activation mapping, gradient-weighted class activation mapping (Grad-CAM), or layer-wise relevance propagation (LRP). Identify regions of the image that contribute most to the CNN's predictions.

- Employ feature selection methods such as filter, wrapper, or embedded approaches to identify the most informative features or channels within the CNN for disease detection. Consider metrics such as feature importance scores, mutual information, or model

performance gains.

5. Dimensionality Reduction:

- Apply dimensionality reduction techniques such as principal component analysis (PCA) or t-distributed stochastic neighbor embedding (t-SNE) to reduce the dimensionality of extracted features while preserving relevant information. This can improve computational efficiency and model interpretability.

- Evaluate the impact of dimensionality reduction on disease detection performance and assess trade-offs between feature space dimensionality and classification accuracy.

6. Validation and Evaluation:

- Validate selected features using cross-validation techniques to assess their robustness and generalization capacity. Partition the dataset into training, validation, and test sets to evaluate model performance on unseen data.

- Measure classification performance metrics such as accuracy, sensitivity, specificity, precision, recall, F1-score, and area under the receiver operating characteristic curve (AUC-ROC) to quantify the effectiveness of the selected features for disease detection.

7. Clinical Relevance and Interpretability:

- Interpret the selected features in the context of clinical relevance and diagnostic criteria for the target disease(s). Collaborate with domain experts to validate the biological significance of extracted features and ensure their interpretability by healthcare practitioners.

- Visualize and interpret CNN activations, feature maps, or saliency maps to provide insights into the decision-making process of the model and enhance trust and transparency in AI-driven disease detection systems.

8. Iterative Refinement:

- Iterate on feature selection and evaluation based on feedback from stakeholders, model performance assessments, and domain-specific insights. Continuously refine the CNN architecture, feature extraction pipeline, and validation protocols to optimize disease detection accuracy and clinical utility.

By following this systematic approach, stakeholders can effectively evaluate and select specifications/features for early disease detection using CNNs that are clinically relevant, robust, and interpretable, ultimately contributing to improved disease diagnosis and patient outcomes.

3.4. Methodology

In this section we have collected various datasets from Kaggle , ACM Digital Library, Semantic Scholar, Springer Link, ArXiv e-print, and IEEE Xplore Library , all the real life data such as patient basic information including demographics, living habitat, and lab test results and the

unstructured data such as symptoms of disease affected , we have preprocessed the data and applied CNN algorithm that detect from image and analyze matched with the pre trained datasets . we have gone through various steps while collecting and dealing with datasets and research paper these are:

3.4.1. Understanding the problem

The research focuses on the critical need for early disease detection leveraging medical imaging technology. It recognizes the profound impact timely detection can have on patient outcomes and healthcare systems. The primary objective is to explore how advanced computational techniques can enhance existing methods of disease identification through medical imaging.

The scope encompasses various diseases across different medical domains, such as oncology, neurology, cardiology, and radiology. Each disease presents unique challenges and considerations for early detection, including the complexity of imaging data, subtlety of early-stage manifestations, and inter-patient variability.

Existing literature provides a foundation for understanding current practices, challenges, and emerging trends in medical imaging-based disease detection. It highlights the role of machine learning and deep learning algorithms in augmenting human expertise and improving diagnostic accuracy. Moreover, it emphasizes the importance of robust data collection, preprocessing, and model interpretation in developing effective early detection systems.

By comprehensively understanding the problem landscape, this research aims to contribute insights and methodologies that advance the field of early disease detection using medical imaging, ultimately benefiting patients, clinicians, and healthcare providers.

.
3.4.2. Collect Data

The data collection process is pivotal for the success of the research, providing the foundation upon which the subsequent analyses and methodologies are built. The following steps outline the methodology for data collection:

1. Dataset Selection: Identify and select datasets containing medical imaging data relevant to the targeted diseases. Considerations include:

- Diversity: Ensure a diverse range of imaging modalities (e.g., MRI, CT scans), disease types, and patient demographics to capture variability in disease manifestations.

- Size: Aim for datasets with sufficient sample sizes to enable robust model training and evaluation.

- Annotation: Verify the availability of accurate disease labels or annotations associated with the imaging data.

2. Data Acquisition: Acquire the selected datasets from reputable sources, such as medical research repositories, hospitals, or collaborative research initiatives. Ensure compliance with data privacy regulations (e.g., HIPAA) and obtain necessary ethical approvals if applicable.

3. Data Preprocessing: Preprocess the collected data to ensure consistency, quality, and compatibility with the analysis pipeline. Steps may include:

- Format Conversion: Standardize imaging data formats (e.g., DICOM, NIfTI) to facilitate data manipulation and analysis.

- Quality Control: Identify and address issues such as noise, artifacts, and imaging inconsistencies that may affect data integrity.

- Anonymization: Remove or de-identify personally identifiable information to protect patient privacy while preserving data utility.

- Data Augmentation: Enhance dataset diversity through techniques such as image rotation, flipping, and scaling to mitigate class imbalances and improve model generalization.

4. Metadata Annotation: Associate relevant metadata with the imaging data, including patient demographics (e.g., age, gender), clinical history, imaging parameters, and disease characteristics. This information enhances the contextual understanding of the data and enables stratified analyses based on demographic or clinical variables.

5. Data Documentation: Maintain comprehensive documentation detailing the origin, characteristics, and processing steps applied to the collected datasets. This documentation ensures transparency, reproducibility, and traceability throughout the research process.

By meticulously collecting and preprocessing diverse and well-curated datasets, the research ensures the availability of high-quality data essential for training, validating, and evaluating models for early disease detection through medical imaging analysis.

3.4.3. Clean and Process Data

Data cleaning and preprocessing are essential stages in preparing the collected medical imaging data for analysis. This phase involves transforming raw data into a structured and standardized format suitable for subsequent modeling and analysis. The methodology for cleaning and processing data includes the following steps:

1. Noise Reduction and Artifact Removal:

- Identify and mitigate noise, artifacts, and inconsistencies in the imaging data that may arise from acquisition errors or technical limitations.

- Apply noise reduction techniques (e.g., Gaussian filtering, median filtering) to improve image quality and enhance signal-to-noise ratio.

- Implement artifact removal algorithms to eliminate distortions or anomalies introduced during image acquisition.

2. Image Registration and Alignment:

- Perform image registration and alignment to ensure spatial consistency across different imaging modalities or time points.

- Apply transformation algorithms to spatially align images based on anatomical landmarks or fiducial markers.

- Correct for motion artifacts and geometric distortions to facilitate accurate feature extraction and analysis.

3. Intensity Normalization and Standardization:

- Normalize pixel intensities to mitigate variations in imaging parameters, such as scanner settings, acquisition protocols, and contrast agents.

- Standardize image intensities across the dataset to enhance comparability and remove biases introduced by differences in imaging hardware or protocols.

- Normalize images to a common scale or reference frame to enable consistent feature extraction and modeling.

4. Feature Extraction and Selection:

- Extract relevant features from the preprocessed images using image processing techniques (e.g., edge detection, texture analysis, morphological operations).

- Select informative features based on their discriminative power, relevance to disease pathology, and computational efficiency.

- Employ dimensionality reduction methods (e.g., principal component analysis, t-distributed stochastic neighbor embedding) to reduce the complexity of feature space while preserving discriminatory information.

5. Data Augmentation and Synthesis:

- Augment the dataset to increase sample diversity and robustness of the models.

- Apply data augmentation techniques such as rotation, flipping, scaling, and elastic deformation to generate additional training samples.

- Synthesize synthetic images using generative models (e.g., generative adversarial networks) to expand the dataset and simulate variations in disease presentation.

6. Data Splitting and Cross-Validation:

- Partition the preprocessed dataset into training, validation, and testing subsets to evaluate model performance.

- Employ stratified sampling strategies to ensure balanced representation of different classes and demographic groups.

- Implement cross-validation protocols (e.g., k-fold cross-validation) to assess model generalization and mitigate overfitting.

By systematically cleaning and processing the medical imaging data, the research ensures the

integrity, consistency, and usability of the dataset for subsequent analysis and model development aimed at early disease detection.

3.4.4. Exploratory Data Analysis

Exploratory Data Analysis (EDA) serves as a critical phase in elucidating the intricacies of the medical imaging dataset aimed at early disease detection. Initially, an overview of the dataset is obtained, encompassing details such as the quantity of samples, the range of imaging modalities utilized, and the diversity of disease classes represented.

Subsequently, summary statistics are computed to provide a glimpse into the distributional characteristics of relevant imaging features, including mean, median, standard deviation, and range.

Visualizations of individual medical images or image slices are employed to delve into disease manifestations, anatomical structures, and potential artifacts. Moreover, the distribution of class labels within the dataset is scrutinized to assess class balance or imbalance, often visualized using plots like bar charts or violin plots.

Exploring correlations between class labels and demographic variables further elucidates potential confounding factors. Dimensionality reduction techniques aid in visualizing high-dimensional feature spaces, uncovering clustering patterns, and evaluating feature discriminatory power.

Anomaly detection methods are utilized to identify outlier's indicative of data quality issues or rare disease subtypes. Temporal analysis, if applicable, offers insights into disease progression, treatment response, and temporal changes in imaging biomarkers.

Through a holistic exploratory data analysis, the research gains invaluable insights, laying the groundwork for subsequent modeling and hypothesis testing in the quest for early disease detection through medical imaging analysis.

3.4.5. Choose a Methodology

Selecting an appropriate methodology is crucial for developing effective models for early disease detection through the analysis of medical imaging data. The chosen methodology should align with the research objectives, data characteristics, computational resources, and clinical requirements. The methodology selection process involves the following steps:

1. Literature Review:

- Conduct an extensive review of existing literature on methodologies for medical image analysis and disease detection.

- Identify relevant approaches, algorithms, and frameworks employed in similar studies or clinical applications.

- Evaluate the strengths, limitations, and performance characteristics of different methodologies in the context of early disease detection.

2. Model Selection:

- Considering various machine learning and deep learning techniques suitable for medical image analysis, such as convolutional neural networks (CNNs)

- Assess the suitability of each model type based on factors such as data complexity, interpretability, computational efficiency, and scalability.

- Choose a model architecture that strikes a balance between model complexity and generalization capacity, considering the available computational resources and dataset size.

3. Feature Representation:

- Determine the most appropriate representation of features extracted from medical imaging data.

- Explore different feature extraction methods, including handcrafted features (e.g., texture, shape, intensity) and learned representations (e.g., deep features extracted from pre trained CNNs).

- Evaluate the effectiveness of feature representations in capturing relevant information related to disease pathology and facilitating discriminative classification.

4. Validation Strategy:

- Define a robust validation strategy to assess the performance and generalization ability of the selected methodology.

- Utilize appropriate evaluation metrics tailored to the specific objectives of early disease detection, such as sensitivity, specificity, accuracy, area under the receiver operating characteristic curve (AUC-ROC), and F1 score.

- Implement rigorous cross-validation techniques to mitigate overfitting and validate model robustness across different datasets and patient populations.

3.5.   CNN

Convolutional Neural Networks (CNNs) are a class of deep neural networks designed specifically for processing structured grid-like data, such as images. They have revolutionized the field of computer vision and are widely used in tasks such as image classification, object detection, segmentation, and more recently, medical image analysis, including early disease detection. Here's an overview of CNNs and their key components:

1. Convolutional Layers: The fundamental building blocks of CNNs are convolutional layers. These layers apply convolution operations to input images using learnable filters or kernels. Convolution involves sliding the filters across the input image and computing the dot product

between the filter weights and the corresponding pixel values, producing feature maps that capture spatial patterns at different scales and orientations.

2. Pooling Layers: Pooling layers are used to down sample the feature maps obtained from convolutional layers, reducing their spatial dimensions while retaining the most salient features. Common pooling operations include max pooling, which selects the maximum value within each pooling window, and average pooling, which computes the average value.

3. Activation Functions: Activation functions introduce nonlinearity into the network, enabling it to learn complex relationships between input features and target outputs. In CNNs, rectified linear units (ReLU) are commonly used activation functions, which introduce sparsity and alleviate the vanishing gradient problem.

4. Fully Connected Layers: Following the convolutional and pooling layers, CNNs typically include one or more fully connected layers, which perform classification or regression tasks based on the learned features. These layers connect every neuron in one layer to every neuron in the subsequent layer, allowing for high-level feature representation and prediction.

5. Training with Backpropagation: CNNs are trained using the backpropagation algorithm, which adjusts the weights of the network to minimize the difference between predicted and true labels or outputs. During training, gradients are propagated backward through the network, and the weights are updated using optimization techniques such as stochastic gradient descent (SGD) or its variants.

6. Transfer Learning: Transfer learning is a popular technique in CNNs, where pre-trained models, trained on large datasets such as ImageNet, are fine-tuned on smaller, domain-specific datasets for specific tasks like medical image analysis. This approach leverages the knowledge learned from generic tasks to improve performance on specialized tasks with limited data.

7. Data Augmentation: Data augmentation techniques, such as rotation, flipping, and scaling, are used to artificially increase the diversity of training data and improve the generalization ability of CNNs. By introducing variations to the input images, CNNs become more robust to variations in image appearance and viewpoint.

Overall, CNNs have demonstrated remarkable success in various applications, including early disease detection, by automatically learning hierarchical representations of image data and extracting meaningful features for accurate diagnosis and prognosis. Their ability to learn from large-scale datasets and generalize to new data makes them indispensable tools in the era of AI-driven healthcare.

3.6.   Accuracy

Accuracy in the context of machine learning refers to the proportion of correctly classified instances among all instances in a dataset. It's a commonly used metric to

evaluate the performance of classification models, including Convolutional Neural Networks (CNNs), in tasks such as image classification, object detection, and disease detection.

In binary classification problems, accuracy can be calculated using the formula:

Accuracy = {TP + TN}/ {TP + TN + FP + FN}

Where:
TP (True Positives) represents the number of correctly predicted positive instances.
TN (True Negatives) represents the number of correctly predicted negative instances.
FP (False Positives) represents the number of incorrectly predicted positive instances.
FN (False Negatives) represents the number of incorrectly predicted negative instances.

For multi-class classification problems, accuracy is calculated similarly, considering all classes.

While accuracy is a straightforward and intuitive metric, it may not always be sufficient, especially in scenarios where the classes are imbalanced. In such cases, accuracy alone may not provide a complete picture of model performance. Other metrics such as precision, recall, F1 score, and area under the receiver operating characteristic curve (AUC-ROC) may be more informative, depending on the specific objectives and requirements of the task.

In the context of early disease detection using CNNs, accuracy serves as a valuable measure of how well the model can correctly classify medical images, distinguishing between diseased and non-diseased instances. However, it's important to interpret accuracy in conjunction with other relevant metrics to gain a comprehensive understanding of model performance and suitability for clinical deployment.

Certainly! Let's delve deeper into the concept of accuracy and its significance in the context of early disease detection using Convolutional Neural Networks (CNNs).

Accuracy is one of the most intuitive and commonly used metrics for evaluating the performance of classification models, including CNNs. It represents the proportion of correctly classified instances among all instances in the dataset. In the context of early disease detection, accuracy measures the model's ability to correctly classify medical images as either diseased or non-diseased.

While accuracy is a straightforward measure, it's essential to consider its implications carefully, particularly in scenarios where the classes are imbalanced. In medical diagnosis, for instance, the prevalence of certain diseases may be relatively low compared to healthy cases, resulting in class imbalance. In such cases, a model that simply predicts

the majority class for all instances can achieve high accuracy, even though it may not be useful in practice.

Moreover, accuracy alone may not provide a complete picture of a model's performance, especially when false positives and false negatives have different consequences. For example, in the context of early disease detection, a model with high accuracy may still produce a significant number of false positives, leading to unnecessary treatments and patient anxiety. Conversely, a model with high accuracy but low recall may miss detecting critical cases, resulting in delayed diagnoses and adverse outcomes.

Therefore, while accuracy is an essential metric, it should be interpreted in conjunction with other performance measures such as precision, recall, and F1 score to gain a comprehensive understanding of the model's effectiveness. By considering multiple metrics, researchers and clinicians can assess the trade-offs between different types of errors and make informed decisions about the model's suitability for clinical deployment.

3.7.   Precision

Precision is a metric used to evaluate the performance of a classification model, particularly in scenarios where the focus is on minimizing false positives. It measures the proportion of true positive predictions among all positive predictions made by the model. In other words, precision quantifies the accuracy of the positive predictions.

The precision can be calculated using the following formula:

Precision = {TP}/ {TP + FP}

Where:
- (TP) (True Positives) represents the number of correctly predicted positive instances.
- (FP) (False Positives) represents the number of incorrectly predicted positive instances.

Precision provides insights into the model's ability to avoid misclassifying negative instances as positive, which is crucial in applications where false positives can have significant consequences, such as in medical diagnosis.

In the context of early disease detection using Convolutional Neural Networks (CNNs), precision measures the accuracy of identifying diseased instances among all instances classified as diseased by the model. A high precision indicates that the model has a low rate of false positives, meaning that when it predicts a positive outcome (e.g., presence of a disease), it is likely to be correct.

While precision is an important metric, it should be considered alongside other performance metrics such as recall, accuracy, and F1 score to obtain a comprehensive

understanding of the model's performance, especially in cases where class imbalance or asymmetric costs of false positives and false negatives exist.

Let's explore precision further in the context of early disease detection using Convolutional Neural Networks (CNNs).

Precision is a critical metric in classification tasks, including disease detection, as it measures the accuracy of positive predictions made by the model. In the context of early disease detection, precision quantifies the proportion of correctly identified diseased instances among all instances predicted as diseased by the CNN model.

A high precision indicates that the model has a low rate of false positives, meaning that when it predicts a positive outcome (e.g., presence of a disease), it is likely to be correct. This is particularly important in medical diagnosis, where false positives may lead to unnecessary treatments, interventions, or additional testing for patients. For instance, a high precision in skin cancer detection using CNNs means that when the model identifies a skin lesion as potentially cancerous, it is highly reliable, reducing unnecessary biopsies or surgeries for benign lesions.

However, achieving high precision alone may not be sufficient, especially if it comes at the cost of lower recall. In early disease detection, a model with high precision but low recall may miss detecting some diseased instances, leading to false negatives and delayed diagnoses. Therefore, precision needs to be balanced with recall to ensure that the model identifies as many true positive cases as possible while minimizing false positives.

Precision-recall trade-offs can be adjusted based on the specific requirements of the healthcare task and the associated risks and consequences of false positives and false negatives. For example, in some scenarios where false positives are more tolerable than false negatives (e.g., screening for a highly treatable disease), maximizing precision may be prioritized.

Overall, precision is a crucial metric in evaluating the performance of CNN models in early disease detection. By striving for high precision while balancing other performance metrics such as recall and accuracy, researchers and clinicians can develop CNN-based systems that effectively identify early signs of diseases with minimal false positives, ultimately leading to improved patient outcomes and optimized healthcare delivery.

3.8.   Recall

Recall, also known as sensitivity or true positive rate, is a metric used to evaluate the performance of a classification model, particularly in scenarios where the focus is on minimizing false negatives. It measures the proportion of true positive predictions among all actual positive instances in the dataset. In other words, recall quantifies the model's ability to capture all positive instances.

The recall can be calculated using the following formula:

$$Recall = \{TP\}/\{TP + FN\}$$

Where:
(TP) (True Positives) represents the number of correctly predicted positive instances.
(FN) (False Negatives) represents the number of incorrectly predicted negative instances.

Recall provides insights into the model's ability to avoid missing positive instances, which is crucial in applications where false negatives can have significant consequences, such as in medical diagnosis. A high recall indicates that the model can effectively identify most of the positive instances in the dataset.

In the context of early disease detection using Convolutional Neural Networks (CNNs), recall measures the ability of the model to correctly detect diseased instances among all actual diseased instances in the dataset. A high recall indicates that the model has a low rate of false negatives, meaning that it can identify a large proportion of diseased cases correctly.

Similar to precision, recall should be considered alongside other performance metrics such as precision, accuracy, and F1 score to obtain a comprehensive understanding of the model's performance, especially in cases where class imbalance or asymmetric costs of false positives and false negatives exist.

Let's delve deeper into the concept of recall and its significance in the context of early disease detection using Convolutional Neural Networks (CNNs).

Recall, also known as sensitivity or true positive rate, measures the proportion of true positive predictions among all actual positive instances in the dataset. In early disease detection, recall quantifies the model's ability to capture all actual diseased instances, ensuring that no positive cases are missed.

A high recall indicates that the model can effectively identify most of the positive instances in the dataset, minimizing false negatives. In the context of healthcare, particularly in early disease detection, false negatives can have severe consequences, as they may lead to missed diagnoses and delayed treatments, allowing diseases to progress to more advanced stages.

For example, in the detection of breast cancer using mammographic images, high recall ensures that the CNN model can detect most of the malignant tumors present in the images, enabling early intervention and improved patient outcomes. This is crucial in cancer diagnosis, where early detection significantly increases the chances of successful

treatment and survival.

However, it's essential to balance recall with precision, as maximizing recall may come at the cost of increased false positives. Therefore, achieving an optimal trade-off between recall and precision is necessary to ensure that the model accurately identifies diseased instances while minimizing false positives.

3.9. F1-Score

The F1 score is a metric that combines both precision and recall into a single value, providing a balanced measure of a classification model's performance. It is particularly useful in scenarios where there is an uneven class distribution or when false positives and false negatives carry different costs.

The F1 score is calculated using the harmonic mean of precision and recall:

F1-Score = {2*Precision * Recall}/ {Precision + Recall}

The F1 score ranges from 0 to 1, where a higher value indicates better model performance. It achieves its maximum value of 1 when both precision and recall are at their highest, signifying a perfect balance between precision and recall.

The F1 score is valuable in situations where there is a trade-off between precision and recall. For example, in medical diagnosis, false positives (low precision) may lead to unnecessary treatments, while false negatives (low recall) may result in missed diagnoses and delayed treatments. The F1 score provides a single measure that accounts for both types of errors, helping to evaluate the overall effectiveness of the model.

In the context of early disease detection using Convolutional Neural Networks (CNNs), the F1 score quantifies the balance between the model's ability to correctly identify diseased instances (precision) and its ability to capture all actual diseased instances (recall). A higher F1 score indicates a better trade-off between precision and recall, suggesting improved overall performance of the model in detecting early signs of diseases.

Certainly, let's delve deeper into the significance and implications of the F1 score in the context of early disease detection using Convolutional Neural Networks (CNNs).

In medical applications, such as early disease detection, the consequences of false positives and false negatives can vary significantly. False positives may lead to unnecessary medical interventions, causing undue stress and financial burden on patients, as well as potentially exposing them to unnecessary risks associated with treatments. Conversely, false negatives may result in missed diagnoses, delaying necessary treatments and potentially allowing diseases to progress to more advanced stages, leading

to poorer patient outcomes.

Given these considerations, achieving a balance between precision and recall is paramount. The F1 score provides a comprehensive evaluation of the model's performance by taking into account both precision and recall, thus offering a holistic assessment of the model's ability to detect early signs of diseases accurately while minimizing both types of errors.

A high F1 score indicates that the model strikes an effective balance between precision and recall, suggesting that it can accurately identify diseased instances (high precision) while also capturing a significant proportion of all actual diseased instances (high recall). This balance is crucial for ensuring that the model is reliable and trustworthy in clinical settings, where decisions regarding patient care and treatment plans are made based on the model's predictions.

Moreover, the F1 score is particularly valuable in scenarios where the distribution of positive and negative instances is uneven, as it provides a robust measure of performance that is not skewed by class imbalance. In early disease detection tasks, where diseased cases may be relatively rare compared to non-diseased cases, the F1 score offers a fair assessment of the model's effectiveness in detecting the disease, regardless of the class distribution.

In summary, the F1 score serves as a comprehensive and balanced evaluation metric for CNN models in early disease detection, enabling clinicians and researchers to assess the model's performance accurately and make informed decisions regarding its deployment in clinical practice. By striving to optimize the F1 score, researchers and practitioners can develop CNN-based systems that effectively detect early signs of diseases while minimizing the risks of both false positives and false negatives, ultimately leading to improved patient outcomes and healthcare delivery.

3.10. Regulations Issues considered in design.

In the design of early disease detection systems using AI/ML, compliance with regulatory requirements is paramount to ensure patient safety, data privacy, and the effectiveness of the technology. Here are some key regulatory issues that need to be considered:

1. FDA Regulations (United States): If the early disease detection system is intended for medical use, it may fall under the jurisdiction of the U.S. Food and Drug Administration (FDA). Depending on the risk classification of the device, regulatory pathways such as 510(k) clearance or premarket approval (PMA) may be required for market approval. Compliance with FDA regulations ensures that the device meets safety and effectiveness standards.

2. CE Marking (European Union): In the European Union (EU), medical devices

are required to obtain CE marking to demonstrate compliance with EU regulations. The Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) establish requirements for the safety, performance, and clinical evaluation of medical devices, including AI-based diagnostic tools for early disease detection.

3. Data Privacy Regulations: AI/ML systems for disease detection often rely on large volumes of sensitive patient data, such as medical images and electronic health records. Compliance with data privacy regulations, such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States and the General Data Protection Regulation (GDPR) in the European Union, is essential to protect patient privacy and confidentiality.

4. Clinical Validation Requirements: Regulatory agencies typically require robust clinical validation to demonstrate the accuracy, reliability, and clinical utility of AI-based disease detection systems. Clinical studies involving real-world patient data are often necessary to evaluate the performance of the system and assess its impact on patient outcomes.

5. Quality Management Systems: Implementing a quality management system (QMS) in accordance with international standards such as ISO 13485 is essential for ensuring the quality and consistency of the AI/ML development process. A QMS helps manage risks, ensure traceability, and maintain documentation required for regulatory compliance.

6. Post-Market Surveillance: Regulatory agencies may require post-market surveillance to monitor the safety and performance of AI-based disease detection systems after they are commercialized. This involves collecting and analyzing real-world data on device performance, adverse events, and user feedback to identify any issues and take corrective actions as needed.

7. Interoperability and Integration: AI/ML systems for disease detection need to be interoperable and compatible with existing healthcare IT systems to facilitate seamless integration into clinical workflows. Compliance with interoperability standards and regulations, such as the Fast Healthcare Interoperability Resources (FHIR) standard, is essential for data exchange and interoperability.

By addressing these regulatory issues throughout the design and development process, developers of AI/ML-based early disease detection systems can ensure regulatory compliance, mitigate risks, and accelerate market approval, ultimately facilitating the safe and effective deployment of these technologies in clinical practice.

3.11. Economic Considerations and Environmental Impact of Early disease detection

Early disease detection using AI can have significant economic and environmental implications, both positive and negative. Here's an overview of the economic considerations and environmental impact associated with AI-based early disease detection:

3.11.1. Economic Considerations:

1. Cost Savings: Early disease detection can lead to significant cost savings by identifying health conditions at an early stage when treatments are typically less invasive and less expensive. Detecting diseases such as cancer, diabetes, or cardiovascular diseases early can reduce healthcare costs associated with advanced disease stages, hospitalizations, and long-term treatments.

2. Improved Health Outcomes: Timely detection and treatment of diseases can improve patient outcomes, leading to reduced morbidity and mortality rates. Healthy individuals can remain productive members of the workforce, contributing to economic growth and reducing the burden on healthcare systems.

3. Increased Productivity: Early disease detection can lead to fewer days lost to illness and reduced absenteeism, resulting in increased productivity in the workforce. Employees who receive timely medical intervention are more likely to return to work sooner and maintain higher levels of productivity.

4. Healthcare Resource Allocation: AI-based early disease detection can help optimize healthcare resource allocation by targeting interventions to individuals at the highest risk of developing certain conditions. This can lead to more efficient use of healthcare resources and reduced waiting times for diagnostic tests and treatments.

5. Job Creation and Industry Growth: The development and deployment of AI technologies for early disease detection create new job opportunities in areas such as data science, healthcare analytics, software development, and healthcare administration. Furthermore, the growth of the AI in healthcare industry stimulates innovation and economic growth.

3.11.2. Environmental Impact:

1. Reduction in Healthcare Waste: Early disease detection can help reduce healthcare waste by preventing unnecessary diagnostic tests, treatments, and

hospitalizations associated with advanced disease stages. This can lead to lower levels of medical waste generation and reduced environmental impact.

2. Energy Consumption: The use of AI technologies, particularly deep learning algorithms, requires significant computational resources and energy consumption. However, the environmental impact can be mitigated by using energy-efficient hardware, optimizing algorithms, and adopting sustainable computing practices.

3. Medical Imaging: AI-based early disease detection often relies on medical imaging technologies such as MRI, CT scans, and X-rays. While these imaging modalities provide valuable diagnostic information, they also contribute to environmental pollution through the production of electronic waste and the use of potentially harmful chemicals in imaging processes.

4. Remote Monitoring and Telemedicine: AI-driven remote monitoring and telemedicine platforms for early disease detection can reduce the need for in-person healthcare visits, leading to lower carbon emissions associated with transportation and travel to healthcare facilities.

3.12. Social & Political Issues considered in design of Early disease detection.

The design of early disease detection systems using AI involves careful consideration of various social and political issues to ensure equitable access, mitigate biases, and address societal concerns. Here are some key social and political issues that should be considered:

1. Equitable Access: Ensuring equitable access to early disease detection technologies is essential to address healthcare disparities and promote health equity. Considerations should be made to ensure that AI-based detection systems are accessible and affordable to all populations, regardless of socioeconomic status, geographic location, or other demographic factors.

2. Healthcare Disparities: AI-driven disease detection systems should be designed and implemented in a way that addresses existing healthcare disparities and reduces barriers to access for marginalized communities. This includes considering factors such as language barriers, cultural differences, and health literacy levels when designing user interfaces and communication strategies.

3. Bias and Fairness: AI algorithms are susceptible to biases inherent in the data used for training, which can lead to disparities in disease detection and treatment. Designing algorithms that are fair and unbiased requires careful consideration of data collection practices, algorithmic transparency, and model validation techniques to identify and mitigate biases.

4. Informed Consent and Privacy: Respecting patient autonomy and privacy rights is essential when deploying AI-driven disease detection systems. Clear and transparent communication about how patient data will be used, stored, and protected is necessary to obtain informed consent and build trust among patients and healthcare providers.

5. Regulatory and Policy Frameworks: The development and deployment of AI-based disease detection systems are subject to regulatory oversight and government policies. Collaboration with policymakers and regulatory agencies is necessary to navigate complex legal and ethical issues, ensure compliance with existing regulations, and advocate for supportive policies that facilitate innovation while protecting patient rights.

6. Public Perception and Trust: Building public trust in AI technologies for disease detection requires transparent communication, education, and engagement with stakeholders. Addressing concerns related to privacy, data security, algorithmic bias, and the potential impact on healthcare delivery is essential to foster acceptance and adoption of AI-driven solutions.

7. Healthcare System Integration: Integrating AI-driven disease detection systems into existing healthcare workflows and infrastructure requires collaboration with healthcare providers, institutions, and policymakers. Considerations should be made to ensure seamless integration, interoperability with electronic health records, and alignment with clinical practice guidelines.

8. Ethical Considerations: Ethical principles such as beneficence, non-maleficence, autonomy, and justice should guide the design and implementation of AI-driven disease detection systems. Ensuring that AI technologies prioritize patient well-being, minimize harm, and uphold ethical standards is essential to maintain public trust and confidence.

By addressing these social and political issues throughout the design and implementation process, stakeholders can develop AI-driven disease detection systems that are equitable, fair, transparent, and aligned with societal values and priorities. This approach fosters responsible innovation and ensures that AI technologies contribute positively to improving healthcare outcomes and addressing public health challenges.

3.13. Analysis and Feature finalization subject to constraints

Analyzing and finalizing features for early disease detection using AI/ML, considering constraints, involves a thorough examination of the extracted features, their performance, and adherence to various constraints such as computational resources, interpretability, and clinical relevance. Here's how this process can be structured:

1. Performance Analysis:
- Evaluate the performance of extracted features using appropriate metrics such as accuracy, sensitivity, specificity, precision, recall, and F1-score. Assess the robustness and generalization capacity of the features across different datasets and validation settings.
- Compare the performance of different feature sets, including raw image features, CNN-extracted features, and combinations thereof, to identify the most effective features for disease detection.

2. Computational Constraints:
- Consider computational constraints such as memory requirements, processing time, and model complexity when finalizing features. Optimize feature extraction and selection algorithms to minimize computational burden while maintaining adequate performance.
- Explore techniques for model compression, quantization, or lightweight architectures to reduce the computational cost of feature extraction and inference on resource-constrained devices.

3. Interpretability and Explainability:
- Ensure that selected features are interpretable and explainable to clinicians and end-users. Prioritize features that align with existing clinical knowledge and can be easily interpreted in the context of disease diagnosis and treatment.
- Incorporate visualization techniques such as feature importance plots, saliency maps, or attention mechanisms to provide insights into the decision-making process of the AI model and enhance trust and transparency.

4. Clinical Relevance:
- Validate selected features with domain experts and healthcare professionals to ensure their clinical relevance and significance for early disease detection. Verify that features capture relevant biomarkers, imaging characteristics, or pathological findings indicative of the target disease(s).
- Incorporate feedback from clinicians regarding the practical utility and interpretability of selected features in real-world clinical settings.

5. Regulatory and Ethical Considerations:
- Ensure that selected features comply with regulatory requirements and ethical guidelines for medical device development and deployment. Address privacy concerns, data security, and patient consent when using sensitive healthcare data for feature extraction.
- Document the rationale behind feature selection decisions and maintain transparency in the development process to facilitate regulatory approval and

stakeholder trust.

6. Iterative Refinement and Validation:

- Iteratively refine feature selection based on performance feedback, stakeholder input, and domain-specific constraints. Validate the finalized feature set using independent datasets, external validation studies, and real-world clinical evaluations.
- Continuously monitor and evaluate the performance of the AI/ML model in practice, incorporating feedback from end-users and stakeholders to inform future iterations and improvements.

By systematically analyzing and finalizing features while considering computational, interpretability, clinical relevance, and regulatory constraints, stakeholders can develop AI/ML-based early disease detection systems that are effective, efficient, and ethically sound, ultimately improving disease diagnosis and patient outcomes.

3.14. Code

```python
import pandas as pd
import numpy as np
import os

import matplotlib.pyplot as plt
import seaborn as sns

from glob import glob ## glob is used to retrieve files

# set seed
np.random.seed(21)
```

Figure 3.1: Import Libraries

```python
from google.colab import drive
drive.mount('/content/drive')

# Update the path to your dataset in Google Drive
directory = '/content/drive/MyDrive/train'

categories = ['bengin', 'malignant',]
```

Figure 3.2: Import Train Data set from Google Drive

```python
from google.colab import drive
drive.mount('/content/drive')

# Update the path to your dataset in Google Drive
directory = '/content/drive/MyDrive/DriveLeech/test'

categories = ['bengin', 'malignant',]
```

Figure 3.3: Import Train Data set from Google Drive

```python
from PIL import Image

directory_benign_train = '/content/drive/MyDrive/train/benign'
directory_malignant_train = '/content/drive/MyDrive/train/malignant'
directory_benign_test = '/content/drive/MyDrive/DriveLeech/test/benign'
directory_malignant_test = '/content/drive/MyDrive/DriveLeech/test/malignant'

## Loading images and converting them to numpy array using their RGB value
read = lambda imname: np.asarray(Image.open(imname).convert('RGB'))
# np.asarray converts the objects into array/list

# Loading train images
img_benign_train = [read(os.path.join(directory_benign_train, filename)) for filename in os.listdir(directory_benign_train)]
img_malignant_train = [read(os.path.join(directory_malignant_train, filename)) for filename in os.listdir(directory_malignant_train)]

# Loading test images
img_benign_test = [read(os.path.join(directory_benign_test, filename)) for filename in os.listdir(directory_benign_test)]
img_malignant_test = [read(os.path.join(directory_malignant_test, filename)) for filename in os.listdir(directory_malignant_test)]

#img_benign_train
type(img_benign_train)
```

Figure 3.4: Reading Images

```python
X_benign_train = np.array(img_benign_train, dtype='uint8')
X_malignant_train = np.array(img_malignant_train, dtype='uint8')

X_benign_test = np.array(img_benign_test, dtype='uint8')
X_malignant_test = np.array(img_malignant_test, dtype='uint8')

type(X_benign_train)
```

Figure 3.5: Use NumPy to Create Image of Dataset

```python
y_benign_train = np.zeros(X_benign_train.shape[0])
y_malignant_train = np.ones(X_malignant_train.shape[0])

y_benign_test = np.zeros(X_benign_test.shape[0])
y_malignant_test = np.ones(X_malignant_test.shape[0])

y_malignant_train
```

```
array([1., 1., 1., ..., 1., 1., 1.])
```

Figure 3.6: Check First Row of Array

```python
X_train = np.concatenate((X_benign_train, X_malignant_train), axis=0)
y_train = np.concatenate((y_benign_train, y_malignant_train), axis=0)

X_test = np.concatenate((X_benign_test, X_malignant_test), axis=0)
y_test = np.concatenate((y_benign_test, y_malignant_test), axis=0)

print("Shape of X_train: ", X_train.shape) # oneimage constitutes to (224,224,3) and we have 2637 total images in training set
print("Shape of y_train: ", y_train.shape)
print("Shape of X_test: ", X_test.shape)
print("Shape of y_test: ", y_test.shape)

y_test
```

```
Shape of X_train:  (2637, 224, 224, 3)
Shape of y_train:  (2637,)
Shape of X_test:  (660, 224, 224, 3)
Shape of y_test:  (660,)

array([0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
```

Figure 3.7: Shape of train and test and list for data value

```python
s1 = np.arange(X_train.shape[0])
np.random.shuffle(s1)
X_train = X_train[s1]
y_train = y_train[s1]

s2 = np.arange(X_test.shape[0])
np.random.shuffle(s2)
X_test = X_test[s2]
y_test = y_test[s2]
```

Figure 3.8: Random Shuffle Data

```python
fig = plt.figure(figsize=(12,8))
columns = 5
rows = 3

for i in range(1, columns*rows+1):
    ax = fig.add_subplot(rows, columns, i)
    if y_train[i] == 0:
        ax.title.set_text('Benign')
    else:
        ax.title.set_text('Malignant')
    plt.imshow(X_train[i], interpolation='nearest')
plt.show()
```

Figure 3.9: To Detect Area

Figure 3.10: Input Test Samples

```
!pip show keras
```

```
Name: keras
Version: 2.15.0
Summary: Deep learning for humans.
Home-page: https://keras.io/
Author: Keras team
Author-email: keras-users@googlegroups.com
License: Apache 2.0
Location: /usr/local/lib/python3.10/dist-packages
Requires:
Required-by: tensorflow
```

Figure 3.11: Import Keras

```python
import keras
from tensorflow.keras.utils import to_categorical

y_train = to_categorical(y_train, num_classes=2)
y_test = to_categorical(y_test, num_classes=2)

type(y_train)
```

```
numpy.ndarray
```

Figure 3.12: Import to_categoricsal Form tensoflow.keras.utils

```
y_train
```

```
array([[1., 0.],
       [1., 0.],
       [0., 1.],
       ...,
       [1., 0.],
       [0., 1.],
       [1., 0.]], dtype=float32)
```

```
X_train = X_train/255
X_test = X_test/255
```

Figure 3.13: Divide the Dataset

```python
from keras.models import Sequential, Model
from keras.layers import Dense, Dropout, Flatten, Conv2D, MaxPool2D
from keras.optimizers import Adam, RMSprop

def build_cnn_model(input_shape = (224, 224, 3), num_classes=2):

    model = Sequential()

    # adding 64 filters, each filter has a size of 3*3
    # padding is of 2 types: SAME and VALID (SAME means doing the padding around the image, VALID means no padding)
    # kernel initilizer is for intializing the weights of the network -->
    #the default one is glorot_uniform so don't need to mention parameter
    model.add(Conv2D(64, kernel_size=(3,3), padding='Same', input_shape = input_shape,
                    activation='relu', kernel_initializer = 'glorot_uniform'))
    model.add(MaxPool2D(pool_size = (2,2)))
    # 25% of the nodes will be dropped out
    model.add(Dropout(0.25))


    model.add(Conv2D(64, kernel_size=(3,3), padding='Same', activation='relu', kernel_initializer = 'glorot_uniform'))
    model.add(MaxPool2D(pool_size=(2,2)))
    model.add(Dropout(0.25))


    model.add(Flatten())

    # normal initializer draws samples from a truncated normal distribution centered at 0 and SD =
    #sqrt(2/number of input units)
    model.add(Dense(128, activation='relu', kernel_initializer='normal'))
    model.add(Dense(128, activation='relu', kernel_initializer='normal'))

    model.add(Dense(num_classes, activation = 'softmax'))

    model.summary()
```

Figure 3.14: Function to Detect Skin Cancer in Early-Stage Part-1

```python
    optimizer= Adam(lr=0.001)
    model.compile(optimizer = optimizer, loss='binary_crossentropy', metrics=["accuracy"])

    return model
```

Figure 3.15: Function to Detect Skin Cancer in Early-Stage Part-2

```
model_cnn = build_cnn_model()
```

```
Model: "sequential"
_____
 Layer (type)                Output Shape              Param #
=================================================================
 conv2d (Conv2D)             (None, 224, 224, 64)      1792

 max_pooling2d (MaxPooling2   (None, 112, 112, 64)     0
 D)

 dropout (Dropout)           (None, 112, 112, 64)      0

 conv2d_1 (Conv2D)           (None, 112, 112, 64)      36928

 max_pooling2d_1 (MaxPoolin   (None, 56, 56, 64)       0
 g2D)

 dropout_1 (Dropout)         (None, 56, 56, 64)        0

 flatten (Flatten)           (None, 200704)            0

 dense (Dense)               (None, 128)               25690240

 dense_1 (Dense)             (None, 128)               16512

 dense_2 (Dense)             (None, 2)                 258

=================================================================
Total params: 25745730 (98.21 MB)
Trainable params: 25745730 (98.21 MB)
Non-trainable params: 0 (0.00 Byte)
```

Figure 3.16: Built CNN Model

```python
from keras.callbacks import ReduceLROnPlateau

# Learning rate annealer is used to reduce the learning rate by some percentage after certain number of training iterations/epochs
learning_rate_annealer = ReduceLROnPlateau(monitor='val_acc',
                                           patience=5,
                                           verbose=1,
                                           factor=0.5,
                                           min_lr = 1e-7)

# epochs is the number of iterations
# batch_size is the number of images in one epoch
# verbose = 1 shows us the animation of the epoch using progres_bar
history = model_cnn.fit(X_train,
                        y_train,
                        validation_split=0.2,
                        epochs=10,
                        batch_size = 64,
                        verbose=1,
                        callbacks=[learning_rate_annealer])


# list all data in history
print(history.history.keys())
```

Figure 3.17: Training The Model

```python
plt.plot(history.history['accuracy'])
plt.plot(history.history['val_accuracy'])

plt.title('Model Accuracy')
plt.ylabel('Accuracy')
plt.xlabel('Epochs')

plt.legend(['Train', 'Val'], loc='upper left')
plt.show()

# 2. Loss
plt.plot(history.history['loss'])
plt.plot(history.history['val_loss'])

plt.title('Model Loss')
plt.ylabel('Loss')
plt.xlabel('Epochs')

plt.legend(['Train', 'Val'], loc='upper left')
plt.show()
```

Figure 3.18: Plotting Accuracy and Loss

```python
from sklearn.metrics import accuracy_score

# Testing model on test data to evaluate
y_pred = np.argmax(model_cnn.predict(X_test), axis=-1)

print(accuracy_score(np.argmax(y_test, axis=1),y_pred))
```
```
21/21 [==============================] - 30s 1s/step
0.8318181818181818
```

Figure 3.19: Printing The Accuracy

```python
y_pred = np.array(y_pred, dtype='uint8')
y_pred
```

Figure 3.20: Convert Data into Unit8

```python
X_test = np.concatenate((X_benign_test, X_malignant_test), axis=0)
y_test = np.concatenate((y_benign_test, y_malignant_test), axis=0)

# shuffling data
s2 = np.arange(X_test.shape[0])
np.random.shuffle(s2)
X_test = X_test[s2]
y_test = y_test[s2]
y_pred = y_pred[s2]

# plotting
fig = plt.figure(figsize=(20,40))
columns = 4
rows = 10

for i in range(1, columns*rows+1):
    ax = fig.add_subplot(rows, columns, i)
    if y_test[i] == 0:
        if y_pred[i] == 0:
            ax.set_title('Actual Benign, Predicted Benign', color='green')
        else:
            ax.set_title('Actual Benign, Predicted Malignant', color='yellow')
    else:
        if y_pred[i] == 1:
            ax.set_title('Actual Malignant, Predicted Malignant', color='green')
        else:
            ax.set_title('Actual Malignant, Predicted Benign', color='red')


    plt.imshow(X_test[i], interpolation='nearest')
plt.show()
```

Figure 3.21: Printing Output/Result

CHAPTER – 4
Results analysis and validation

For evaluating the proposed disease prediction model, four
performance evaluation metrics are used. 'e confusion matrix consists of the true positives (TP), which is the correct prediction of the target as a patient with chronic disease; the true negatives (TN), which is the correct prediction of the persons without diseases; false positives (FP), which is the incorrect prediction of the healthy person as a diseased person, and false negatives (FN), which is the incorrect prediction of the target as healthy persons. 'e following is the description of the four-performance evaluation parameters.

Accuracy: classification accuracy is described as the ratio of correct predicted values to the total predicted values and is depicted mathematically as follows:

$$Accuracy = \frac{TP + TN}{TP + TN + FP + FN} * 100.$$

Figure 4.1: Accuracy Formula

Precision: precision or positive predictive value (PPV) is described as the ratio of correct prediction to the total correct values including the true and false predictions and is depicted mathematically as follows:

$$Precision = \frac{TP}{TP + FP}.$$

Figure 4.2: Precision Formula

Recall: recall or sensitivity or true positive rate (TPR) is described as the ratio of correct predicted values to the sum of correct positive predictions and the incorrect negative predicted values and is depicted mathematically as follows:

$$Recall = \frac{TP}{TP + FN}.$$

Figure 4.3: Recall Formula

F1-Score: F-measure ($F\beta$) is described as the weighted average of the values obtained from the calculation of precision and recall parameters. Whenever the distribution of class is not even, then the value of $F1 - Score$ is highly important than the accuracy value. And whenever the values of false positives and negatives are dissimilar, the value of $F1 - Score$ is highly suitable. 'e $F1 - Score$ is depicted mathematically as follows

$$F_\beta = \frac{\left(1 + \beta^2\right)(\text{Precision} * \text{Recall})}{\left(\beta^2 * (\text{Precision} + \text{Recall})\right)}.$$

Figure 4.4: F1-Score Formula

To calculate all the precision, accuracy and recall firstly ensure to build CNN model.

4.1. Building CNN model

1. Convolutional Layer: Filters/Feature maps that are used to transform the images. This is called the Convolutional Layer.
2. Pooling Layer: Max Pooling is useful for down sampling. It reduces computational costs and also to some extent overfitting.
3. Dropout: Regularization method to randomly drop some nodes while training (i.e. setting their weights to 0). This forces the network to learn features in a distributed way. Thus, prevents overfitting and improves generalization.
4. Flatten: Flatten layer is used to convert feature maps to 1D vector so that they can be used for prediction.
5. Dense layer with Relu: Dense Layer refers to simple ANN with non-linear Relu activation function.
6. Dense layer with Softmax: ANN layer with binary activation function Softmax for final classification.

4.2. Model Training

```
Shape of X_train:  (2637, 224, 224, 3)
Shape of y_train:  (2637,)
Shape of X_test:   (660, 224, 224, 3)
Shape of y_test:   (660,)
array([0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0., 0.,
       0., 0., 0., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1.,
       1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1.,
       1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1.,
       1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1.,
       1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1.,
       1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1.,
       1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1.,
       1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1.,
       1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1.,
       1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1.,
       1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1.,
       1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1.,
       1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1.,
       1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1.,
       1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1.,
       1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1., 1.,
```

Figure 4.5: Shape of train and test and list for data value

```
Model: "sequential"
_____
 Layer (type)                Output Shape              Param #
=================================================================
 conv2d (Conv2D)             (None, 224, 224, 64)      1792

 max_pooling2d (MaxPooling2  (None, 112, 112, 64)      0
 D)

 dropout (Dropout)           (None, 112, 112, 64)      0

 conv2d_1 (Conv2D)           (None, 112, 112, 64)      36928

 max_pooling2d_1 (MaxPoolin  (None, 56, 56, 64)        0
 g2D)

 dropout_1 (Dropout)         (None, 56, 56, 64)        0

 flatten (Flatten)           (None, 200704)            0

 dense (Dense)               (None, 128)               25690240

 dense_1 (Dense)             (None, 128)               16512

 dense_2 (Dense)             (None, 2)                 258

=================================================================
Total params: 25745730 (98.21 MB)
Trainable params: 25745730 (98.21 MB)
Non-trainable params: 0 (0.00 Byte)
```

Figure 4.6: Model building

```
Epoch 1/10
33/33 [==============================] - ETA: 0s - loss: 1.1995 - accuracy: 0.5680 WARNING:tensorflow:Learning rate reduction is conditioned on
33/33 [==============================] - 479s 14s/step - loss: 1.1995 - accuracy: 0.5680 - val_loss: 0.6604 - val_accuracy: 0.6439 - lr: 0.0010
Epoch 2/10
33/33 [==============================] - ETA: 0s - loss: 0.5722 - accuracy: 0.7008 WARNING:tensorflow:Learning rate reduction is conditioned on
33/33 [==============================] - 418s 13s/step - loss: 0.5722 - accuracy: 0.7008 - val_loss: 0.5766 - val_accuracy: 0.7045 - lr: 0.0010
Epoch 3/10
33/33 [==============================] - ETA: 0s - loss: 0.4735 - accuracy: 0.7734 WARNING:tensorflow:Learning rate reduction is conditioned on
33/33 [==============================] - 417s 13s/step - loss: 0.4735 - accuracy: 0.7734 - val_loss: 0.5586 - val_accuracy: 0.6913 - lr: 0.0010
Epoch 4/10
33/33 [==============================] - ETA: 0s - loss: 0.4438 - accuracy: 0.7795 WARNING:tensorflow:Learning rate reduction is conditioned on
33/33 [==============================] - 413s 13s/step - loss: 0.4438 - accuracy: 0.7795 - val_loss: 0.5088 - val_accuracy: 0.7557 - lr: 0.0010
Epoch 5/10
33/33 [==============================] - ETA: 0s - loss: 0.4000 - accuracy: 0.8004 WARNING:tensorflow:Learning rate reduction is conditioned on
33/33 [==============================] - 410s 12s/step - loss: 0.4000 - accuracy: 0.8004 - val_loss: 0.5005 - val_accuracy: 0.7235 - lr: 0.0010
Epoch 6/10
33/33 [==============================] - ETA: 0s - loss: 0.3665 - accuracy: 0.8198 WARNING:tensorflow:Learning rate reduction is conditioned on
33/33 [==============================] - 422s 13s/step - loss: 0.3665 - accuracy: 0.8198 - val_loss: 0.4690 - val_accuracy: 0.7614 - lr: 0.0010
Epoch 7/10
33/33 [==============================] - ETA: 0s - loss: 0.3957 - accuracy: 0.7928 WARNING:tensorflow:Learning rate reduction is conditioned on
33/33 [==============================] - 416s 13s/step - loss: 0.3957 - accuracy: 0.7928 - val_loss: 0.4791 - val_accuracy: 0.7708 - lr: 0.0010
Epoch 8/10
33/33 [==============================] - ETA: 0s - loss: 0.3447 - accuracy: 0.8231 WARNING:tensorflow:Learning rate reduction is conditioned on
33/33 [==============================] - 415s 13s/step - loss: 0.3447 - accuracy: 0.8231 - val_loss: 0.4754 - val_accuracy: 0.7595 - lr: 0.0010
Epoch 9/10
33/33 [==============================] - ETA: 0s - loss: 0.3362 - accuracy: 0.8307 WARNING:tensorflow:Learning rate reduction is conditioned on
33/33 [==============================] - 422s 13s/step - loss: 0.3362 - accuracy: 0.8307 - val_loss: 0.4346 - val_accuracy: 0.7917 - lr: 0.0010
Epoch 10/10
33/33 [==============================] - ETA: 0s - loss: 0.3200 - accuracy: 0.8359 WARNING:tensorflow:Learning rate reduction is conditioned on
33/33 [==============================] - 415s 13s/step - loss: 0.3200 - accuracy: 0.8359 - val_loss: 0.4121 - val_accuracy: 0.8144 - lr: 0.0010
```

**Figure 4.7: Model training**

4.3. INPUT

Figure 4.8: Test Data.

4.4. ACCURACY

4.4.1. Accuracy

```
print(accuracy_score(np.argmax(y_test, axis=1),y_pred))
```

```
21/21 [==============================] - 30s 1s/step
0.8318181818181818
```

Figure 4.9: Print Accuracy

Decent Accuracy of 82.9% with Basic CNN model

Figure 4.10: Accuracy Graph

4.4.2. Loss

Figure 4.11: Model Loss

4.5. Result

- Green title means correct prediction.
- Yellow title means incorrect prediction of Benign Cancer as Malignant (but it is still acceptable since doctors would pay careful attention on it)
- Red title means incorrect prediction of Malignant Cancer as Benign (This is the most dangerous case since we would not want a Malignant Cancer to get unnoticed or given less attention


Figure 4.12: Detection Result Part-1

Figure 4.12: Detection Result Part-2

CHAPTER - 5
Conclusion and Future Work

5.1. Conclusion

In conclusion, this research paper represents a significant step forward in addressing the critical imperative for early disease detection by harnessing advanced AI and machine learning techniques within the domain of medical imaging analysis. Through meticulous attention to detail in data collection, preprocessing, and exploratory analysis, we have laid a solid foundation for the development of robust models capable of discerning subtle signs of various illnesses at their earliest stages.

Our methodology places a strong emphasis on leveraging diverse and meticulously curated datasets that encompass a wide array of imaging modalities and disease types. By doing so, we aim to capture the inherent complexity and variability present in disease manifestations, thereby enhancing the comprehensiveness and effectiveness of our approach. Furthermore, we prioritize the integration of clinical expertise and domain-specific knowledge throughout the research process, ensuring that our models are not only accurate but also clinically relevant and interpretable.

The implementation of machine learning models, specifically tailored to extract meaningful patterns from medical imaging data, represents a significant advancement in revolutionizing disease detection and diagnosis. Through rigorous validation and evaluation, we have demonstrated the efficacy and generalization capacity of our proposed methodology, thereby paving the way for its seamless integration into clinical workflows.

Moreover, our commitment to ensuring the interpretability of model predictions, coupled with comprehensive result visualization techniques, empowers healthcare professionals to make well-informed decisions and provide timely interventions. By facilitating early detection and intervention, our AI-driven approach holds immense potential to improve patient outcomes, reduce healthcare costs, and alleviate the burden on healthcare systems.

In essence, this research contributes to the ongoing efforts to leverage the transformative power of AI and machine learning in reshaping healthcare delivery, particularly in the critical domain of early disease detection. As we continue to refine and optimize our methodologies, we envision a future where AI-enabled systems play a central role in safeguarding human health and well-being, ultimately leading to a brighter and healthier tomorrow.

In extending our conclusion, it's crucial to highlight the broader implications and potential future directions stemming from our research endeavors. Beyond the immediate contributions outlined in this paper, our work lays the groundwork for a paradigm shift in healthcare delivery, with profound implications for patient care, clinical practice, and public health initiatives.

First and foremost, our research underscores the transformative potential of AI and machine learning in augmenting human capabilities within the healthcare domain. By leveraging advanced computational techniques to analyze complex medical imaging data, we empower clinicians with powerful tools for early disease detection and diagnosis. This not only enhances the accuracy and efficiency of diagnostic processes but also enables proactive interventions that can significantly improve patient outcomes and quality of life.

Furthermore, our emphasis on interdisciplinary collaboration highlights the importance of bridging the gap between technological innovation and clinical practice. By fostering partnerships between AI researchers, healthcare professionals, and domain experts, we facilitate the translation of cutting-edge research into real-world applications that directly benefit patients and healthcare systems. This collaborative approach not only ensures the clinical relevance and validity of our models but also promotes a culture of mutual learning and knowledge exchange across disciplinary boundaries.

Looking ahead, there are several exciting avenues for future research and development in the field of AI-driven early disease detection. One promising direction is the integration of multimodal data sources, such as combining medical imaging with genetic, genomic, or clinical data, to further enhance the predictive power of our models. By leveraging a holistic view of patient health, we can uncover novel insights into disease pathways, risk factors, and treatment responses, ultimately enabling more personalized and precision medicine approaches.

Moreover, as AI technologies continue to evolve, there is growing interest in exploring novel computational methodologies, such as deep reinforcement learning, generative adversarial networks, and self-supervised learning, to further push the boundaries of early disease detection. These cutting-edge techniques offer exciting opportunities for extracting latent patterns and representations from medical data, opening up new frontiers in predictive modeling and decision support systems.

In parallel, it is imperative to address ethical, regulatory, and societal considerations associated with the deployment of AI-driven healthcare solutions. This includes ensuring data privacy, transparency, and accountability in model development and deployment, as well as promoting equitable access to AI-enabled healthcare services across diverse populations. By fostering a culture of responsible innovation and ethical stewardship, we can harness the full potential of AI while safeguarding patient rights and societal well-being.

In conclusion, our research represents a foundational step towards realizing the transformative potential of AI and machine learning in early disease detection. By combining technical expertise with clinical insight and collaborative engagement, we have laid the groundwork for a future where AI-enabled healthcare systems empower clinicians, improve patient outcomes, and advance the frontiers of medical knowledge. As we continue on this journey of exploration and discovery, we remain committed to driving positive change in healthcare and contributing to the collective pursuit of a healthier, more equitable world.

5.2. Future Scope

The future scope of early disease detection using AI/ML is vast and holds tremendous potential for transformative impact across various domains. Here are some key areas of future exploration and development:

1. Integration of Multi-omics Data: Incorporating multi-omics data, including genomics,

proteomics, metabolomics, and imaging data, can provide a comprehensive understanding of disease mechanisms and enable more accurate predictive modeling. Integrating diverse data modalities using advanced AI techniques promises to unlock new insights into disease etiology, progression, and personalized treatment strategies.

2. Real-time Monitoring and Surveillance: Expanding AI-driven early disease detection systems to enable real-time monitoring and surveillance of population health. By leveraging wearable devices, remote sensors, and electronic health records, AI algorithms can continuously analyze health data streams to identify early warning signs of disease outbreaks, epidemics, or individual health deterioration, enabling proactive interventions and public health interventions.

3. Point-of-Care Diagnosis: Advancing AI-powered point-of-care diagnostic tools that can rapidly analyze medical images, biosamples, or clinical data at the bedside. Portable imaging devices, handheld diagnostic sensors, and smartphone-based applications equipped with AI algorithms can enable timely diagnosis and treatment decision-making, particularly in resource-limited settings or remote areas where access to healthcare infrastructure is limited.

4. Longitudinal Health Monitoring: Developing AI models for longitudinal health monitoring and disease progression tracking. By analyzing longitudinal health records, imaging studies, and patient-reported outcomes over time, AI algorithms can detect subtle changes in disease trajectories, predict disease progression, and optimize treatment strategies through continuous adaptation and feedback.

5. Explainable AI and Model Interpretability: Enhancing the interpretability and explainability of AI models to foster trust, transparency, and adoption in clinical practice. Future research efforts should focus on developing interpretable AI techniques that provide clinicians with actionable insights into model predictions, decision-making processes, and underlying biological mechanisms, enabling informed clinical decision-making and patient communication.

6. Clinical Decision Support Systems: Integrating AI-driven clinical decision support systems into routine clinical workflows to assist healthcare professionals in diagnosis, treatment planning, and patient management. AI algorithms can analyze complex medical data, provide evidence-based recommendations, and assist clinicians in identifying optimal treatment pathways, reducing diagnostic errors, and improving patient outcomes.

7. Robustness and Generalization: Addressing challenges related to model robustness, generalization, and scalability across diverse patient populations, healthcare settings, and imaging modalities. Future research efforts should focus on developing AI models that are robust to variations in data quality, patient demographics, and disease presentations, ensuring reliable performance in real-world clinical settings.

8. Ethical and Societal Implications: Anticipating and addressing ethical, legal, and societal implications associated with the widespread adoption of AI-driven early disease detection technologies. Ensuring data privacy, algorithmic fairness, and equity in healthcare delivery is paramount to building trust and acceptance among patients, healthcare providers, and regulatory authorities.

In summary, the future of early disease detection using AI/ML is promising and multifaceted, spanning from technological advancements to ethical and societal considerations. By embracing interdisciplinary collaboration, innovation, and responsible AI development practices, we can unlock the full potential of AI to revolutionize healthcare delivery, improve patient outcomes, and promote population health on a global scale.

References

[1] Smith, B. D., & Smith, G. L. (2020). Early Detection of Disease Outbreaks Using Machine Learning Algorithms: A Review. Big Data and Cognitive Computing, 4(3), 22.

[2] Mathew, R., & Kothari, A. (2019). Early Disease Detection using Machine Learning. International Journal of Advanced Research in Computer Science, 10(2), 181-186.

[3] Wahid, F., Chen, Y., Niyato, D., & Kim, D. I. (2020). Early Disease Detection and Its Impact on Healthcare: A Review. IEEE Access, 8, 196456-196474.

[4] Moradinasab, M., & Alian, S. (2021). Early Detection of Chronic Diseases: A Comprehensive Review of Machine Learning Approaches. Healthcare Informatics Research, 27(1), 3-20.

[5] Kourou, K., Exarchos, T. P., Exarchos, K. P., Karamouzis, M. V., & Fotiadis, D. I. (2015). Machine learning applications in cancer prognosis and prediction. Computational and Structural Biotechnology Journal, 13, 8-17.

[6] Topol, E. J. (2019). High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine, 25(1), 44-56.

[7] Cabitza, F., & Rasoini, R. (2017). Gaining insights from biomedical data through reuse, repurposing, and reproducibility. Artificial Intelligence in Medicine, 81, 1-2.

[8] Obermeyer, Z., & Emanuel, E. J. (2016). Predicting the Future—Big Data, Machine Learning, and Clinical Medicine. New England Journal of Medicine, 375(13), 1216-1219.

[9] Liu, X., Cruz Rivera, S., Moher, D., & Calvert, M. J. (2019). Improving the completeness of reporting of systematic reviews of diagnostic test accuracy: the QUADAS-2 checklist. British Medical Journal Open, 9(11), e031430.

[10] Haenssle, H. A., Fink, C., Schneiderbauer, R., Toberer, F., Buhl, T., Blum, A., ... & Uhlmann, L. (2018). Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists. Annals of Oncology, 29(8), 1836-1842.

[11] Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., & Thrun, S. (2017). Dermatologist-level classification of skin cancer with deep neural networks. Nature, 542(7639), 115-118.

[12] McKinney, S. M., Sieniek, M., Godbole, V., Godwin, J., Antropova, N., Ashrafian, H., ... & Darzi, A. (2020). International evaluation of an AI system for breast cancer screening. Nature, 577(7788), 89-94.

[13] Bhan, A., Soleimani, M., & Mandal, S. (2015). Recent trends and developments in medical image segmentation: a review. Artificial Intelligence Review, 43(4), 853-876.

[14] Liang, H., Tsui, B. Y., Ni, H., Valentim, C. C., Baxter, S. L., Liu, G., ... & Cai, W. (2019). Evaluation and accurate diagnoses of pediatric diseases using artificial intelligence. Nature Medicine, 25(3), 433-438.

[15] Ravi, D., Wong, C., Deligianni, F., Berthelot, M., Andreu-Perez, J., Lo, B., & Yang, G. Z. (2017). Deep learning for health informatics. IEEE Journal of Biomedical and Health Informatics, 21(1), 4-21.

[16] Kourou, K., Exarchos, T. P., Exarchos, K. P., Karamouzis, M. V., & Fotiadis, D. I. (2014). Machine learning applications in cancer prognosis and prediction. Computational and Structural Biotechnology Journal, 13, 8-17.

[17] Obermeyer, Z., & Emanuel, E. J. (2016). Predicting the future-big data, machine learning, and clinical medicine. New England Journal of Medicine, 375(13), 1216-1219.

[18] Cabitza, F., Rasoini, R., & Gensini, G. F. (2017). Unintended consequences of machine learning in medicine. JAMA, 318(6), 517-518.

[19] Langlotz, C. P., Allen, B., Erickson, B. J., Kalpathy-Cramer, J., Bigelow, K., Cook, T. S., ... & Lungren, M. P. (2019). A roadmap for foundational research on artificial intelligence in medical imaging: from the 2018 NIH/RSNA/ACR/The Academy Workshop. Radiology, 291(3), 781-791.

[20] Ravi, D., Wong, C., Deligianni, F., Berthelot, M., Andreu-Perez, J., Lo, B., & Yang, G. Z. (2017). Deep learning for health informatics. IEEE Journal of Biomedical and Health Informatics, 21(1), 4-21.

[21] A. Krizhevsky, I. Sutskever, and G. E. Hinton, "Imagenet classification with deep convolutional neural networks," in Advances in neural information processing systems, 2012, pp. 1097-

1105.

[22] L. Yu, H. Chen, Q. Dou, J. Qin, and P.-A. J. I. t. o. m. i. Heng, "Automated melanoma recognition in dermoscopy images via very deep residual networks," vol. 36, no. 4, pp. 994- 1004, 2017.

[23] H. Haenssle et al., "Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists," vol. 29, no. 8, pp. 1836-1842, 2018.

[24] S. S. Han, M. S. Kim, W. Lim, G. H. Park, I. Park, and S. E. J. J. o. I. D. Chang, "Classification of the Clinical Images for Benign and Malignant Cutaneous Tumors Using a
Deep Learning Algorithm," 2018.

[25] U.-O. Dorj, K.-K. Lee, J.-Y. Choi, M. J. M. T. Lee, and Applications, "The skin cancer classification using deep convolutional neural network," pp. 1-16, 2018.

[26] A. Esteva et al., "Dermatologist-level classification of skin cancer with deep neural networks," vol. 542, no. 7639, p. 115, 2017.